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Cardiac arrest (CA) and subarachnoid hemorrhage (SAH) are devastating neurovascular 
diseases with high mortality. Patients who survive the initial insult frequently have long-term 
neurological deficits. Delayed ischemia is recognized as one of the important mechanisms 
underlying poor outcome; however, strategies to improve cerebral perfusion failed to 
demonstrate efficacy in long-term outcome.  Regulation of vascular tone in the cerebral 
microvasculature is key in determining cerebral blood flow (CBF), therefore, the evaluation of 
cerebral microcirculation alterations after CA and SAH can provide insights into the 
pathophysiology of neurovascular diseases and aid in the discovery of promising therapeutic 
targets.  
The aim of this dissertation is to explore the role of cerebral microvascular alterations in 
an animal model and patients who are subjected to neurovascular diseases.  In Chapter 2, we 
extensively reviewed the pharmacological therapies used for CA and global ischemia. We 
believe that combination therapy is promising which maximizes the effect of CBF restoration 
and off-sets potential adverse effects on cerebral microcirculation.  In Chapter 3 and 4, we 
established an in-vivo multiphoton microscopy platform to evaluate the pathophysiology and 
pharmacology in a pediatric CA model.  We observed the capillary no-reflow phenomenon and 
prolonged plasma mean transit time (MTT) in-vivo, identified arteriolar constriction and red 
blood cell (RBC) stasis as two potential targets to restore cerebral perfusion after CA.  Inhibition 
of a vessel constrictive fatty acid, 20-HETE, dilated arterioles and attenuated MTT but had no 
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effect on RBC stasis.  Our results suggest the need for combination therapy to mitigate both the 
arteriolar constriction and the no-reflow phenomenon.  In Chapter 5, we assessed 20-HETE and 
CO2 reactivity as two microcirculatory biomarkers in SAH patients. Plasma 20-HETE was not 
correlated with cerebrospinal fluid level, suggesting that local production of 20-HETE might 
underline the pathophysiology of SAH.  We also found a wide range of CO2 reactivity in SAH 
patients which paved the way for future clinical biomarker investigation.  
Collectively, this work identified new therapeutic targets in cerebral microcirculation, 
and provides rationale for CBF targeted treatment for neurovascular diseases. The clinical 
biomarker investigation provides novel insights in identifying vulnerable patient population to 
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1.0  INTRODUCTION AND BACKGROUND 
 2 
1.1 INTRODUCTION 
The theme of this dissertation is to better understand the pathophysiology of neurovascular 
diseases, such as cardiac arrest (CA) and subarachnoid hemorrhage (SAH).  Secondary ischemia 
is a common complication accompanied with CA and SAH and is attributed to mortality and 
morbidity.  We are determined to investigate the cerebral blood flow (CBF) after CA and SAH 
and trying to identify novel therapeutic targets to ultimately improve patient outcome.  In chapter 
1, we provided a brief introduction of CBF alterations after CA since it is the disease we focused 
on in chapter 2-4. The introduction of SAH will be illustrated with more details in chapter 5.  
1.2 CARDIAC ARREST OVERVIEW  
Cardiac arrest (CA) is the cessation of systemic circulation due to trauma, drug overdose, 
drowning, asphyxia, cardiovascular or other medical causes. More than 356,500 and 209,000 
people suffer from out-of-hospital and in-hospital CA annually in the United States [1]. Despite 
the recent gradual improvement in survival, CA remains a significant cause of death with only 
11.4% patients who survive to discharge [1].   
Brain injury caused by CA contributes to 68% and 23% mortality in out-of-hospital and 
in-hospital CA [2, 3]. Patients that survive the initial CA often suffer from prolonged 
neurological dysfunction, including coma and persistent vegetative state. It was estimated that 
only 3-7% survivors are able to return to their previous level of function, which creates an 
enormous economical and societal burden on patients, their family and health care system [4, 5]. 
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1.3 CEREBRAL BLOOD FLOW AFTER CARDIAC ARREST 
The ischemic perfusion that follows CA subjects the brain tissue to hypoxia and leads to 
neuronal damage. Cerebral blood flow (CBF) is a key component during and after resuscitation 
to provide sufficient perfusion and oxygen supply. Disturbances in CBF post-CA have been 
recognized in numerous clinical studies as well as pre-clinical animal models [6]. Classically, 
CBF post-resuscitation can be described into three phases: early hyperemia, followed by 
hypoperfusion, and finally either resolution of normal blood flow or protracted hyperemia [7].  
Recently, detailed temporal and regional CBF alterations after CA was depicted using MRI. 
Manole, et al. reported early hyperemia in the subcortical region and sustained hypoperfusion in 
the cortical region in a pediatric asphyxial CA model [8].  Different animal models, age, injury 
severity have also been attributed to CBF variations [6, 8, 9].  
1.4 CBF REGULATION 
Regulation of CBF is multifactorial. CBF is direct proportional to the cerebral perfusion pressure 
(CePP) and inversely related to cerebral vascular resistance (CVR) (Eq. 1). CePP is the driving 
force of blood flow in the brain and is determined by the difference between the mean arterial 
pressure (MAP) and intracranial pressure (ICP) (Eq. 2).  As described by Poiseuille[10], CVR is 
affected by the length of the vessel (L), blood viscosity (η) and vessel radium (r) (Eq. 3). Change 
in any of these factors can impact CBF.  
                                                                                                        (Eq. 1) 
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                                                                                             (Eq. 2) 
                                                                                                                (Eq. 3) 
1.5 RESUSCITATION MANAGEMENT  
Ever since cardiopulmonary resuscitation (CPR) was implemented in 1960s, the guidelines for 
modern resuscitation have evolved based on emerging preclinical and clinical evidence. The 
primary goal of resuscitation during CA is to provide perfusion to critical organs (heart and 
brain) with a final goal of restoring and maintaining spontaneous perfusion. Pharmacologic 
therapies such as vasopressors, antiarrhythmic drugs, atropine, sodium bicarbonate, calcium 
(Ca2+), and magnesium have been used clinically and in animal models to facilitate resuscitation 
[11]. Various therapies were utilized to optimize CBF post-resuscitation. 
1.6 CARDIAC ARREST ANIMAL MODELS 
CA leads to a global ischemia injury. To mimic the global ischemic status, early animal models 
such as aortic balloon occlusion [12] and neck tourniquet insults [12] were studied. Recently, 
clinically relevant animal models were established including ventricular fibrillation (VF) CA, 
asphyxial CA and KCL induced CA [9, 13, 14]. Most studies were conducted in small or large 
animal models, including rats, mice, rabbits, cats, dogs, pigs, sheep and monkeys [15-17]. 
Animal models enable the serial and regional assessment of CBF and also provide the advantage 
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of correlating CBF and CBF targeted interventions with thorough histology and outcome 
evaluations. On the other hand, species, age and gender differences can attribute to CBF 
variations observed in different studies. Cautions should be taken when interpreting results on 
different animal models. 
1.7 DIFFERENT METHODOLOGY FOR CBF ASSESSMENT 
Both invasive and non-invasive methodologies have been utilized to study CBF or perfusion 
post-CA. Some methodologies are only applied in animal models while some others can also be 
used at bedside. A more detailed description of different methodology can be found elsewhere 
[7].  In animal models, radiolabeled microspheres, laser-speckle flowmetry, and optical imaging 
are often adopted [17-20]. Multiphoton microscopy is a novel imaging method which enables 
detailed observation in the cerebral microcirculation [21].  Although CBF is not routinely 
monitored for patients who survive from CA, methods available for CBF assessment in human 
includes transcranial doppler, arterial spin labeling MRI, Xenon-CT, and near-infrared 
spectroscopy [6, 22-25].  Different methodologies provide different features as well as 
limitations for CBF assessment. These advantage and limitations add another layer of complexity 
in different studies.  
CBF directed therapies post-CA have the potential to restore nutrition supply and 
attenuate neuronal damage.  Indeed, therapies targeted at both early hyperemia and 
hypoperfusion have shown benefit in outcomes [13, 26-28]. We propose here to analyze the 
impact of previously published CBF-directed therapies on CBF and neurological outcome post-
CA with special attention to details of the experimental protocol as it relates to the species used, 
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CA model, regional and temporal changes in perfusion, as well as specific microcirculatory 
alterations.  The detailed presentation of CBF directed therapies grouped according to the 
physiological parameters impacted will be summarized in chapter 2. 
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2.0  PHARMACOLOGICAL THERAPIES TARGETED ON CEREBRAL BLOOD FLOW 





Major strides were made during the last decades in improving the rates of resuscitation from CA 
by optimizing CPR techniques and maximizing CPR education in laypersons. Important 
advances also occurred in the optimization of post-CA physiological care, including institution 
of hypothermia, maintenance of temperature regulation and blood pressure. While hypoxic-
ischemic encephalopathy is the major limiting factor for intact neurological survival after CA, 
cerebral-specific therapies have not been instituted at a large scale to date. There is a pressing 
need for novel interventions to improve CBF after CA to prevent secondary injury and improve 
overall outcomes.  As several pharmacological therapies have been explored in preclinical 
models and some therapies have been explored in patients, we identified the need to synthetize 
the effects of pharmacologic therapeutic interventions to date as they relate to the regulation of 
CBF.  Development of such interventions requires a thorough understanding of the factors that 
are known to regulate CBF and the effects of current pharmacologic therapies. Therefore, the 
purpose of this chapter is to summarize the current evidence for pharmacological therapies that 
targeted CBF restoration after CA or global ischemia models and discuss the potential for future 
development.  
To identify published articles on CBF-directed therapies, we initially developed a 
comprehensive search strategy (Appendix I). This search strategy yielded 1063 articles from 
PubMed database published until Dec 2018. We analyzed 665 studies in animal models and 28 
clinical studies. A flowchart of our results is presented in Figure 2.1. Two reviewers screened the 
titles and abstracts, identified and analyzed relevant articles, and categorized these articles into 
five classes generated a priori based on the therapeutic mechanism and site of action. The 
categories included: flow promotion therapies (maximize CePP), vasodilatory (maximize CVR), 
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thrombolytic (mitigate capillary stasis), antioxidant and anti-inflammatory (maintain homeostasis 
of the endothelial cells), and other hemodynamic therapies (combination therapies or other 
mechanisms) (Figure 2.1). These therapies are also summarized in Appendix II. 
 
Figure 2.1 Flowchart of the results from the PubMed database 
2.2 FLOW PROMOTION THERAPIES  
The flow promotion therapies have the goal to improve CBF by maximizing CePP either via 
increasing the cardiac output or MAP s According to Eq.1 and 2, increasing MAP will enhance 
CePP and CBF. This class of therapies can be further categorized as adrenergic agents and non-
adrenergic agents.  
 10 
2.2.1 Adrenergic Agents 
Most adrenergic agents exert a “fight or flight” response: increased blood pressure, 
vasoconstriction in most vascular beds, vasodilation in skeletal muscles, heart and brain, 
increased heart rate, and bronchodilation. The effect of each specific adrenergic agent is 
determined by the type of adrenergic receptor stimulated (ARs) and the affinity to each receptor. 
The four major adrenergic receptors are α-1, α-2, β-1 and β-2. Alpha-1 receptors are localized 
postsynaptically in sympathetic nerves and are expressed in the smooth muscle throughout the 
body [29, 30] They mediate the cardiovascular sympathetic responses to stress.  The major effect 
of α-1 receptor activation is smooth muscle contraction in blood vessels including vessels of the 
heart and brain. Alpha-1 receptors also mediate glycogenolysis and gluconeogenesis responses. 
Alpha-2 adrenergic receptors are expressed in both peripheral tissue and central nervous system 
and are localized pre-synaptically at the terminals of the sympathetic nerves. When activated,  α-
2 ARs inhibit the release of endogenous agonist norepinephrine (NE) and attenuate the 
sympathetic response [31]. The physiological effects of α-2 ARs include decreased peripheral 
vascular resistances, decreased insulin release and increased glucagon release. Beta-1 adrenergic 
receptors are the predominant receptors in cardiac smooth muscles and control cardiac function 
through positive inotropic and chronotropic effects, producing increased contractility and 
tachycardia,  while β-2 receptors mediate smooth muscle relaxation,  bronchodilation and 
glycogenolysis when activated [30]. When autoregulation is intact, cerebral vasoconstriction 
mediated by vascular α receptors is not significant [30, 32]. In contrast, coronary blood flow is 
enhanced by both α and β-2 receptor stimulation [30]. The effects of adrenergic agents on 
myocardial function during resuscitation were previously described [32-34], and thus we will 
focus on the effect of adrenergic agents on CBF during and after resuscitation.  
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Epinephrine (Epi) has been used clinically as standard of care at resuscitation for more 
than 40 years [35]. As a non-selective adrenergic receptor agonist, Epi activates all four 
receptors’ isoforms with different affinity. Epi has a higher affinity for β than α receptors, 
therefore, at low Epi doses, β-1 and β-2 receptor mediated responses dominate, while at high 
dose, α-1, α-2 receptor mediated responses predominate. At the Epi dose used for resuscitation, α 
receptor mediated response is the primary effect, manifested as enhanced aortic diastolic 
pressure, which increases coronary perfusion pressure (CPP) and CePP. CPP has been strongly 
associated with successful return of spontaneous circulation (ROSC) in both humans and animals 
[36, 37].  In a ventricular fibrillation (VF) CA model in piglets Epi increased CPP in a dose-
dependent manner [38]. At a higher Epi dose of 0.09 mg/kg, CPP almost doubled, and survival 
success was approximately six times higher than at a low Epi dose of 0.015 mg/kg, suggesting 
the potent α-1 activation of the higher dose. The potent cardiac vasoconstriction of Epi increased 
blood pressure and CePP, leading to increased CBF (Eq.1).  Epi administered at resuscitation 
increased cortical CBF more than six-fold post-CA, and increased cerebellar and midbrain CBF 
tenfold [39]. Similar to the effect on CPP, Epi also exerts a dose dependent effect on CBF. Pigs 
that received high Epi dose of 2.0 mg/kg at resuscitation from VF CA had four to five-fold 
higher CBF in cortex, cerebellum and midbrain compared with pigs that received a low Epi dose 
of 0.02 mg/kg [39]. Epi also improves CBF and cerebral O2 uptake in pediatric CA models after 
resuscitation [40]. 
Epi has a short half-life of 2-3 minutes. To sustain its flow promoting effect, multiple 
dosing strategies were investigated in CA models. Studies have suggested that Epi increases CBF 
in a dose dependent manner: higher doses are associated with higher CBF and resuscitation rates 
[39-42]. The Epi doses evaluated range from 0.015 ~ 2.0 mg/kg. Different dosing regimens of 
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Epi and their effect on CBF were also evaluated in animal models. When dosed repeatedly after 
resuscitation, each bolus of Epi was observed to have a transient CBF increment [43]. 
Continuous Epi infusion led to more a sustained increment in cortical CBF compared with 
repeated doses [44]. However, long-term neurological assessments were not performed in those 
studies, and in the context of recent human studies showing no neurological benefit in Epi-
treated groups vs. controls these evaluations are needed. 
More recently, the effect of Epi on CBF has been questioned in the cerebral 
microcirculation, mostly due to its prolonged α-1 mediated peripheral vasoconstriction. Ristagno 
et al. found that cortical microcirculatory blood flow was largely reduced after 0.03 mg/kg Epi 
treatment in a pig model of CA [45].  The evaluation was based on images obtained in piglets 
though a cranial window placed on the surface of the cortex, and only visible surface vessels 
were assessed. The Ristagno group also reported that epinephrine, due to its α-1 agonist effect, 
decreased PbO2 tension and increased PbCO2 tension and worsened tissue ischemia[46]. Other 
effect of Epi in cerebral microcirculation is still under investigation. With more advanced 
imaging methods such as arterial spin label MRI and multiphoton microscopy, the effects of Epi 
treatment as it relates to dose on cerebral microcirculation after CA can be better elucidated.  
In addition to the effect of Epi on CBF when given at after resuscitation, the effect of Epi 
during the post-CA period has been evaluated in pre-clinical studies. Epi administered at 3 h 
after resuscitation in a pediatric CA model markedly increased CBF in all brain regions, likely 
secondary to loss of autoregulation [8].  
Other adrenergic agents with effect on CBF evaluated post-resuscitation from CA include 
NE, phenylephrine, methoxamine and dexmedetomidine. Similar to Epi, NE is also a non-
selective adrenergic receptor agonist and can activate α-1, α-2 and β1-receptors, and thus can 
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also increase heart rate, cardiac contractile force and blood pressure, therefore promote CBF. 
Lindner, et al. reported that NE administration significantly increased CePP in a swine CA where 
CBF was assessed using microspheres. CBF increased from 30 mL/min/100g to 58 mL/min/100g 
after NE administration [47]. NE is a weak β-2 AR agonist, so NE was not expected to increase 
glycogenolysis after resuscitation. In this study, both NE and Epi increased CBF and oxygen 
delivery to a similar extent, but neither increased cerebral oxygen consumption. Phenylephrine 
and methoxamine are two pure α-1 agonists. They are expected to constrict cardiac smooth 
muscle and increase CePP during resuscitation thus promoting CBF. Phenylephrine at  10 mg/kg 
improves CBF post-CA to a similar extent as Epi 0.2 mg/kg administration [48],  while at 
phenylephrine dose of 0.1 mg/kg, the cortical CBF is only 1/6 of the CBF after Epi 
administration [40]. Methoxamine at a dose of 10 mg/kg can only partially restore CBF up to the 
caudal structure such as the pons, medulla and cervical spinal cord [49]. These results suggest 
that α-1 activation alone produces modest increases in CBF and thus is potentially not sufficient 
for flow promotion to the brain after CA. The positive inotropic and chronotropic effect of β-1 
AR might also play an important role. Dexmedetomidine is an α-2 AR agonist with good brain 
penetration profile. The rationale of using dexmedetomidine is to attenuate α-1 AR responses in 
the brain and reduce CRV. When dexmedetomidine was administered after resuscitation with 
phenylephrine in a canine model of 5 min CA, pial arterioles dilated up to 15 min post-CA but 
no difference was found in oxygen extraction post resuscitation [42]. Since CBF or metabolism 
were not directly measured in this study, the decreased oxygen extraction might be due to the 
impaired metabolism. Compared with Epi, other adrenergic agents have only been evaluated 
over a limited dose range with limited CBF assessment available. Furthermore, additional studies 
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to evaluate the effects of other adrenergic agents on long-term outcome assessments are needed 
to determine overall therapeutic efficacy.  
Overall, adrenergic agents have a role in promoting CBF post-CA. It is critical to restore 
the spontaneous perfusion to the brain as soon as possible. Currently, adrenergic agents are the 
only pharmacological agents able to attain this, and need to be dosed immediately at the 
resuscitation. However, prolonged α-1 AR responses may lead to sustained cerebral 
vasoconstriction, which could result in increased CVR and compromised CBF. Prolonged α-1 
and β-2 activation could also worsen ischemia by stimulating oxygen consumption. It might be 
plausible to use adrenergic agents at resuscitation and suspend after ROSC is achieved.  
The efficacy of adrenergic agents to promote CBF after CA has been demonstrated in 
multiple animal models, however their direct effect on microcirculation remains an important 
and largely unexplored.  With the emergence of more powerful methodologies such as Arterial 
Spin Label MRI for regional CBF assessment and in vivo multiphoton microscopy for direct 
microcirculatory assessment, a more thorough evaluation of the role of adrenergic agents is 
possible.  
2.2.2 Non-adrenergic Agents 
The effect of non-adrenergic agents can be mediated by both the adrenergic α1, β2 receptors, and 
also by specific dopaminergic, vasopressin, …etc receptors.  
Dopamine (DA) plays a major role in the central nervous system by regulating motor and 
cognitive function. DA also has vascular effects mediated by DA receptors and cross interaction 
with ARs. At low concentration, DA activates vascular D1 receptors, elevates intracellular 
cAMP and mediate vasodilation. At intermediate concentration, DA can increase perfusion by 
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interactions with both β-1 receptors and D1 receptors. At high concentrations, DA has cross 
interaction with α receptors in the smooth muscle and produce vasoconstriction. Liu et al. found 
that DA administration improved MAP and oxygen metabolism after 30min ROSC in a 4min 
VFCA swine model[50]. In this study, CPP increased 33% after 1-hour ROSC but CBF 
measurement was not performed. The improved CPP might be a combination of both α-1 ARs 
and D1 activation. Similar to Epi, cautions also arise for the potential deleterious effect of 
prolonged α-1 receptor activation which could constrict peripheral arterioles and compromise 
CBF.   
Vasopressin is an endogenous hormone synthesized in hypothalamus and released into 
the blood stream. The major effect of vasopressin includes arterial constriction and increasing 
water reabsorption during hypertonicity [51]. Vasopressin does not share crossover activation 
with ARs. There are three types of vasopressin receptors: V1a, V1b and V2. The vascular effect 
of vasopressin is predominantly mediated by V1a receptor expressed in smooth muscle cells [52]. 
V1a receptor belongs to G-protein coupled receptor family. When V1a is activated, downstream 
pathways, including phospholipase C (PLC), inositol-1,4,5-trphosphate (IP3), protein kinase C 
(PKC) pathways, will increase intracellular Ca2+ level, causing depolarization and muscular 
contraction [53]. In the heart, vasopressin can cause coronary vasoconstriction and increased 
CPP although controversial observation does exist [54, 55]. In the brain, vasopressin is mostly 
considered a potent vasoconstrictor for arteries and arterioles [56]. White topical application of 
vasopressin constricted pial arterioles in anesthetized rabbits [57], vasopressin also shown to 
exert a biphasic action with an initial potent vasoconstriction mediated by V1 receptors, followed 
by vasodilation mediated by V2 receptors [58]. Dose- and vessel size-dependent effect of 
vasopressin has been reported where vasopressin dilates large arteries at low, physiological dose 
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[57, 59]. Such dilatory effect has been attributed indirectly to nitric oxide (NO) pathway [60]. At 
a high dose of 40 mU/kg given intravenously, Faraci et al. showed that the resistance of large 
arteries decreases while resistance of small arterioles increases [57]. Vasopressin therefore could 
be preferred in promoting perfusion pressure with cerebral vasodilation in large cerebral arteries. 
Vasopressin does not share crossover activation with ARs, therefore it could increase 
cardiac perfusion, but not myocardial oxygen demand. Accumulating clinical studies and animal 
experiments suggest the benefit of vasopressin over Epi after CPR [61-64]. Vasopressin 
administration increased aortic diastolic pressure after 4 min CA compared with saline control 
and with  Epi, which suggests potent coronary vasoconstriction and increased CPP[65]. 
Vasopressin also ameliorated neurodegeneration in these piglets as assessed by MRI. Several 
other studies investigated the effect of vasopressin on CBF and found equivalent or even better 
results compared with Epi. In a prolonged porcine CA model, vasopressin resulted in a two-fold 
increase in myocardial blood flow at 90s and 5 min after ROSC compared with Epi. CBF was 
found to be 3.5 and 6.3 times higher as compared with Epi at 90 s and 5 min after ROSC, 
respectively [63]. In a pediatric 8 min asphyxial CA model, both CPP and CBF increased more 
than two-fold after vasopressin administration but was comparable to Epi treatment [62]. A study 
by Nozari, et al. showed in a 5 min VFCA model that vasopressin injection led to ~30% higher 
cortical CBF compared to Epi, while CPP and CePP are similar between two treatment groups, 
indicating the reduction of CVR after vasopressin treatment [66]. The exact values and extent of 
CPP and CBF promotion effect of vasopressin are different across studies, which could be due to 
different animal models and quantification methodology.  
Recently, the effect of vasopressin on microcirculatory blood flow has gained more 
attention. Using orthogonal polarization spectral imaging through a cranial window in pigs 
 17 
treated with vasopressin at resuscitation, a 5 times increase in the number of perfused cortical 
microvessels was observed after vasopressin treatment compared with Epi [64]. At the same 
time, improved microcirculatory flow index and brain tissue oxygenation were observed at 5 min 
after vasopressin administration compared with Epi treatment [46]. Although vasopressin has 
been suggested to provide advantages in cerebral microcirculatory flow and outcome after CA 
resuscitation, its superiority over Epi as a vasopressor has not been established.  Vasopressin 
administration was found with suboptimal endocardial perfusion and myocardial hypoperfusion 
[46].  Although supportive preclinical studies exist, there is a need for additional clinical 
evaluation to determine if vasopressin improves overall cerebral blood flow.  
Endothelin (ET) is a family of four vasoactive peptides produced in endothelium. ET-1 
is the predominant isoform and constrict vessels by activating two types of ET receptors: ETA 
and ETB receptors. Both ETA and ETB receptors are localized in the vascular smooth muscle 
while ETB receptors are also found in endothelial cells and macrophages [54, 67, 68]. Activation 
of both ETA and ETB receptors results in vasoconstriction. The mechanism of action includes 
PLC activation, leading to accumulation of inositol triphosphate and intracellular Ca2+ [69]. ETB 
receptor also exerts vasodilation by stimulating NO production on the endothelium. ETA is the 
predominant isoform in the heart and mediates positive inotropic effect by activating protein 
kinase C and the Na+/H+ exchanger [70]. ET receptors are also found in cerebral blood vessel, 
choroid plexus and peripheral nerves so ET-1 is considered a potent cerebral vasoconstrictor 
mediated by Ca2+ channels [70].  
A thorough study by DeBehnke investigated the effect of ET-1 at a dose of 50, 150 and 
300 µg, respectively, with or without Epi after 10min VFCA[71]. CPP was found higher (85 vs 
28 mm Hg) in pigs receiving 300 µg ET-1 injection compared with pigs receiving Epi. More 
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than 4 times higher regional and global CBF was observed in pigs receiving 150 and 300 µg ET-
1 than pigs receiving Epi. These results suggest that ET-1 promotes CBF by increasing CePP, 
exerting dose-dependent, positive inotropic effect mediated by ETA. Another study by Holzer, et 
al. confirmed the dose-dependent promotion of ET-1 on CPP and CBF in a 5 min VFCA in 
swine [72]. In these two studies, the flow promotion effect of ET-1 manifests within 10 min after 
injection. However, concerns rise for ET-1 with worsened outcome post resuscitation, mainly 
due to the persistence of the vasoconstrictor effect. A pharmacokinetic model with radiolabeled 
ET revealed that ET-1 is distributed and cleared in a complicated three-compartment model and 
can remain in the body up to 45 hours [73]. Another study also described prolonged 
vasoconstrictive effect compared with ET-1 plasma concentration due to extremely slow 
dissociation from binding site [74]. Hilwig and colleagues reported that ET-1 substantially 
increased CPP during CPR but the mean pulse pressure dropped to less than 10 mm Hg after 1 
hour ROSC [75]. ETA antagonist BQ123 injected at 15 min ROSC improved long-term 
neurological outcome after CA, which further questioned the application of endothelin-1 as an 
appropriate flow promotion agent during resuscitation [76, 77]. 
Angiotensin (ANG) II is an endogenous octapeptide and widely involved in 
physiological activities including vasoconstriction, blood pressure regulation, inflammation, and 
platelet aggregation [78]. Two G-protein-coupled receptors, ANG type 1 receptor (AT1R) and 
ANG type 2 receptor (AT2R), have been identified as the main types of ANG receptors. Most of 
the effects of ANG II are mediated by AT1R, which is distributed in various organs, including 
liver, heart, brain, kidney, adrenals and vasculature [79]. Acutely accumulated ANG II can 
activate AT1R and produce vascular smooth muscle constriction. The mechanism includes 
activation of downstream PLC, phospholipase A2 (PLA2), IP3 and diacylglycerol (DAG). 
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Within seconds, IP3 can subsequently increase intracellular Ca2+ level and cause smooth muscle 
cell contraction[79]. Meanwhile DAG can activate PKC and also contribute to vasoconstriction. 
In addition, activated PLA2 can further form arachidonic acid (AA) and produce a range of 
vasoactive metabolites: prostaglandins, leukotrienes, epoxyeicosatrienoic acids (EETs) and 
hydroxyeicosatetraenoic acids (HETEs). ANG II can also activate NAD(P)H oxidases and 
produce reactive oxygen species (ROS) [80]. 
Similar to other flow promotion agents, ANG II also increase blood pressure and CBF by 
constricting large arteries. Little and Brown showed that ANG II administration increased CBF 
from 6.9 mL/min per 100 g to 30.8 mL/min per 100 g in a pediatric piglet VFCA model using 
radiolabeled microspheres [81]. However, the CBF promotion effect has not been evaluated in 
comparison with other vasopressors. It is difficult to determine the relative potency and efficacy 
of ANG II compared with other agents based on the currently published literature. Moreover, 
ANG II might not serve as a preferred flow promotion agent because of its wide range of 
physiological effects. Unwanted effects such as ROS production, platelet aggregation and 
sustained vasoconstriction might compromise the benefit of ANG on flow promotion.   
In summary, several non-adrenergic agents have also been used during resuscitation for 
CA. Their flow promotion effects provide novel mechanisms to improve CBF but also bring in 
new challenges. So far, no superior effect has been recognized compared with Epi. More long-
term outcome and off-target effect remains to be investigated. 
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2.3 VASODILATORY THERAPIES 
This class of therapies dilate peripheral vessels, reducing CVR and improve CBF post-CA. 
According to Eq.3, vasodilator strategies have the potential to have great efficacy to increase 
CBF.  Multiple mediators participate in the change of vessel diameter such as glutamate, NO, 
adenosine, ions like hydrogen (H+), potassium (K+), Ca2+ and vasoactive fatty acids [82, 83]. The 
molecular pathways of these mediators are complex and sometimes overlapping. A single agent 
can improve perfusion through cross-talk activation of multiple pathways simultaneously or 
sequentially. As will be highlighted in the forthcoming section, it is notable that most of agents 
in this class also possess neuroprotection independent from the CBF effect.  
2.3.1 NO Pathway 
NO is a key signaling molecule in the vasculature produced by various cell types including 
endothelial cells, platelets, macrophages, and neurons. Three isoforms of nitric oxide synthase 
(NOS) are responsible for the synthesis of NO: endothelial NOS (eNOS), neuronal NOS (nNOS) 
and inducible NOS (iNOS). Both eNOS and nNOS transiently produce NO at nanomolar level in 
a Ca2+ dependent manner, while iNOS is less Ca2+ sensitive and produces NO at the micromolar 
range. Biochemical stimuli such as thrombin, acetylcholine and bradykinin, and mechanical 
stimuli such as shear stress and cyclic strain can increase NO synthesis. It is generally considered 
that the low local levels of NO produced by eNOS are cytoprotective and the high concentrations 
of NO produced by iNOS are cytotoxic [84].  
After formation, NO diffuses to adjacent vascular smooth muscle cells and exerts 
vasorelaxation. The fundamental mechanism of NO is through guanylyl cyclase activation which 
 21 
increases cGMP formation and activates PKG [85]. NO can also inhibit voltage-gated Ca2+ 
channels and activate Ca2+denpendent K+ channel [86, 87]. Both effects result in reduction in 
cytosolic Ca2+ level and vasodilation. Additional mechanisms of NO vasodilation include the 
inhibition of vasoconstrictive pathways, such as ANG II and 20-HETE [88, 89]. In the heart, NO 
exerts a dual inotropic effect and a positive chronotropic effect [90]. At low concentrations, NO 
enhances myocardial contractility while at high concentrations it depresses contractility. In the 
brain, NO is a key mediator in regulating CBF at rest, during physiological conditions, as well as 
under pathophysiological conditions [86]. It is generally recognized that eNOS derived NO plays 
an essential role in autoregulation by maintaining basal vascular tone. NO derived from nNOS 
appears more involved in neurovascular coupling [91]. In addition to its well-known vasodilatory 
effect, NO also exerts antiplatelet, antithrombotic, anti-inflammatory, and antioxidant properties. 
Therapies targeting NO pathway include NO donors and various NOS inhibitors 
(Appendix II). The rationale to use NO donors, including inhaled NO, L-arginine, sodium 
nitroprusside, and nitroglycerin, is to increase NO level, dilate peripheral vessels and decrease 
CVR. Direct inhalation of NO can supply intravascular NO and has been shown greatly 
improved survival rate when initiated up to 2 hours in a CA model in mice [91]. However, CBF 
did not increase in the cortex, hippocampus or whole brain when evaluated with ASL-MRI, 
probably due to systemic vasorelaxation and decreased CePP. L-arginine serves as a substrate for 
all NOS. Hiramatsu and Tsui, both reported that L-arginine increased CBF ~50% accompanied 
with improved oxygen metabolism in two pediatric piglet CA models [92, 93]. Sodium 
nitroprusside is clinically used to treat acute hypertensive crises due to its potent vasodilatory 
effect. Schultz, et al. suggested that sodium nitroprusside produces 2-fold increased CPP and 4 -
fold increased CePP in a 15 min VFCA swine model [94]. Yannopoulos, et al. further confirmed 
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improved CPP with improved survival rate and neurological outcome in an 8 min swine model 
[95]. Nitroglycerin is a prodrug which releases NO after bioactivation and cause vasodilation 
[96]. Nitroglycerin improved the neurological outcome given alone in an 8 min asphyxial CA 
model in rats [97]. However, CBF post-CA has not been assessed after nitroglycerin treatment 
alone. Combination therapy of nitroglycerin with either epinephrine or vasopressin has shown 
benefits in protection of myocardial blood flow and endocardial perfusion in two swine CA 
models [98, 99]. More importantly, the combination therapies lead to improved CBF and 
functional outcome after CA [100-102]. In a 6 min asphyxial CA study, delayed use of 
nitroglycerin in addition to vasopressin produced better resuscitation rate than vasopressin alone, 
proposing that the optimal dosing strategy of nitroglycerin to avoid MAP decrease is delayed 
administration, as the potential deleterious effects common for NO donors could be prolonged 
systemic hypotension [103].  
Multiple NOS inhibitors have been investigated in the CA models focused on mitigating 
some of the unwanted pathophysiological effects of NO. Glutamate release in early ischemia 
leads to activation of nNOS and iNOS, producing massive amount of NO, which can interact in 
direct equimolar concentrations with superoxide to form neurotoxic peroxynitrite [102, 104]. The 
rationale to use NOS inhibitors is to prevent the excessive production of NO by nNOS and 
iNOS. On the other hand, reduction of NO by NOS inhibitors can lead to vasoconstriction both 
in the heart and in the brain. L-nitro-arginine methyl ester (L-NAME), is a non-selective NOS 
inhibitor which has been shown to reduce blood flow by 25% and increase resistance by 50% in 
humans [105]. In a swine model of CA, L-NAME injected at reperfusion showed no change in 
CBF[106]. Two other studies in pediatric piglets reported decreased CBF after L-NAME 
injection at resuscitation[94, 107], which was likely due to the observed ~2 fold increased MAP 
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and ~2.5 increased CVR as reported by Hiramatsu [93]. Methylene Blue inhibits NO synthesis 
as well as guanylyl cyclase activity and have been suggested to counteract with NO by 
attenuating cGMP mediated vasodilation [94, 108]. However, the study by Miclescu et al. 
measured cortical CBF using laser-Doppler and reported almost doubled cortical CBF after 12 
min CA in pigs [109]. Such effect could be attributed to the additional inotropic effect of 
methylene blue as reported earlier[110]. 7-nitroindazole(7-NI) and L-N(5)-(1-
iminoethyl)ornithine (L-NIO) are selective nNOS and eNOS inhibitors, respectively. Several 
studies have shown that nNOS inhibition by 7-NI reduces NO concentration in the brain and 
reduced neuronal damage while eNOS inhibition by L-NIO is detrimental after global ischemia 
[111-113]. However, neither 7-NI nor L-NIO affected CBF, suggesting that the effect of these 
two NOS inhibitors are not flow dependent.  
NO regulation is complex given the dichotomous effects of neuroprotection and 
neurotoxicity. The benefit of CBF improvement of NO could be compromised by the deleterious 
interaction with ROS. Elucidation of pathways to specifically increase CBF without altering the 
ROS generation and neuronal survival are needed to identify effective methods of 
neuroprotection with NO pathway modulation. 
2.3.2 Adenosine 
Adenosine is an endogenous purine nucleoside which exerts a wide range of physiological 
activities such as coronary vasodilation, antithrombotic property and regulation of the 
sympathetic nervous system [114]. The effects of adenosine occur through four adenosine 
receptors: A1, A2A, A2B and A3. Activation of A1 and A3 receptors reduces adenyl cyclase 
activity and decreases intracellular cAMP. A potent vasodilatory effect is mainly mediated by 
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A2A and increase cAMP levels in the vascular bed [115]. Adenosine also shares cross interactions 
with the NO and adrenergic systems [116]. By dilating coronary arteries, adenosine can increase 
coronary flow and myocardial oxygen tension. Xu, et al. reported that adenosine dosed 
immediately after resuscitation induced hypothermia, improved CBF and survival in rats 
subjected to 12 min CA [117]. Such beneficial effect in CBF could be attributed to reduced 
temperature and/or vasodilation. Of note, adenosine administration can cause bradyarrhythmias 
[118], and endogenous adenosine released by myocardial cells during ischemia is also implicated 
to cause or perpetuate bradyasystole in CA [119].  Hence, due to its mixed cardiac profile, 
adenosine is not commonly used as a vasodilator after CA.   
2.3.3 Calcium Channel Blockers  
Calcium is a central determinant of membrane potential and regulate vascular tone [120, 121]. 
As mentioned in previous sections, Ca2+ also serves as a key secondary messenger for multiple 
therapeutic agents.  
During ischemia, however, the Ca2+ hemostasis is disrupted by multiple ion channels and 
receptors dysfunction, which leads to a massive shift of Ca2+ from extracellular spaces into 
intracellular compartments and exacerbates the ischemic injury [122, 123]. Calcium channel 
blockers are expected to block the excessive influx of Ca2+, reducing Ca2+ overload, producing 
membrane hyperpolarization and vasorelaxation.  
Nimodipine binds specifically to L-type voltage-gated Ca2+channels and acts 
preferentially on cerebral vessels [124].  Schindler, et al. reported that nimodipine injected at 
resuscitation produces almost twice higher CBF at 10 minutes ROSC in pigs subjected to 5min 
VFCA [125]. The CBF increment of nimodipine obtained in animal models was also seen in a 
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randomized clinical study with improved CBF 4 hours post arrest using Xenon CT [126].  
Diltiazem is also a Ca2+ channel blocker with high affinity for coronary vasculature [127]. The 
negative inotropic, chronotropic, and dromotropic effects of diltiazem provides potential benefit 
of reduced oxygen consumption in the heart. When dosed at 5 min after ROSC, diltiazem 
increased CBF on both hemispheres over 2 hours ROSC in an asphyxial CA model [125].  In this 
study, the oxygen consumption index remained unchanged compared with placebo, suggesting 
the impaired metabolism which could not be reversed by diltiazem treatment. Flunarizine is a 
Ca2+ antagonist which has relative low affinity to voltage-gated Ca2+channels but binds to 
calmodulin and dilate peripheral vessels [128]. Two canine VFCA studies demonstrated that 
flunarizine, given immediately after reperfusion, improved post-resuscitation CBF [125, 129]. 
The improved CBF persisted for 1.5 and 4 hours, respectively, in these two studies. Significant 
reduced neurological deficit was also reported after flunarizine treatment [130].  Levosimendan 
is a Ca2+ sensitizer, exerts positive inotropic effect by increasing the Ca2+ sensitivity in 
myocytes. Levosimendan can also dilate vessel by opening ATP-dependent K+-channel [130]. 
Both positive inotropic and vasodilatory effects could potentially improve CBF by increasing 
perfusion pressure and reducing CVR. A study by Kelm et al. showed that continuous infusion 
of levosimendan leads to improved CBF and outcome in rats subjected to asphyxial CA [131]. 
Calcium homeostasis is complex because of the essential role as a secondary messenger 
which involves in various biological processes. Calcium channels are widely distributed, and 
calcium channel blockers’ effect on heart calcium receptors may produce unwanted effects of 
reduced cardiac output. In fact, multiple randomized clinical studies in CA patients failed to find 
benefit in neurological outcome or survival rate after Ca2+ channel blocker treatments, indicating 
that Ca2+ channel blockers alone might not improve the outcome [127, 132-134]. Neurotoxicity 
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was also found in calcium channel blockers [135]. More investigation should be performed to 
explore the role of Ca2+ channel blockers in the cerebral microcirculation, providing mechanistic 
rationale to support the use of Ca2+ channel blockers. 
2.3.4 Glutamate Receptor Antagonists 
Glutamate is a prominent excitatory neurotransmitter in the central nervous system. The effect of 
glutamate is mediated by four classes of receptors: N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), Kainate, and metabotropic receptors.  
NMDA, AMPA and Kainate receptors are ionotropic receptors which enable ion flow across 
membranes to maintain plasticity and potential. During early ischemia, accumulated extracellular 
glutamate activates glutamate receptors excessively, leading to excitotoxicity and neuronal death 
[136]. By antagonizing glutamate receptor activity, it is expected to reduce excitotoxicity and 
neuronal damage. However, glutamate receptor antagonists administration after CA has reported 
both beneficial [137-139] and deleterious effects [138, 140-142]. Pre-treatment with MK-801, a 
noncompetitive NMDA receptor antagonist, and NBQX, an AMPA receptor antagonist, increase 
vascular resistance and depress CBF at baseline [143, 144]. Moreover, CBF and oxygen 
consumption remained lower after resuscitation in NBQX group, suggesting exacerbated 
ischemic injury [145]. The application of glutamate receptor antagonists is not supported with 
current evidence, probably due to early onset of excitotoxicity.  
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2.3.5 Vasoactive Fatty Acids  
As previous described, PLA2 cleaves AA from phospholipids under ischemic condition and 
other pathophysiological conditions. Released AA is quickly metabolized through 
cyclooxygenase (COX), lipoxygenase (LOX) pathways, and by cytochrome (CYP) P450 
enzymes into vasoactive prostaglandins, leukotrienes, EETs, and HETEs [144, 146]. Strategies 
have targeted specific fatty acids with the goal of improving CBF in CA models. For example, 
the metabolite 20-HETE is a potent vasoconstrictor for small arteries playing a key role in 
regulating CBF in the microcirculation [147, 148]. The mechanism of 20-HETE vasoconstriction 
is mediated by depolarization of vascular smooth muscle membrane secondary to blocking the 
large-conductance Ca2+-activated K+-channels [149-151] and stimulation of the L-type Ca2+ 
channel [152, 153].  More recently, direct effects of 20-HETE were described in apoptosis [90], 
neuroinflammation and superoxide production pathways [154, 155].  Shaik, et al. demonstrated 
that treatment of HET0016, which specifically inhibits the formation of 20-HETE, improved 
cortical CBF by ~25% assessed by laser speckle flowmetry in a pediatric asphyixal CA model 
[156].  Favorable histological outcome and neurological outcome were also reported in the same 
study. 20-HETE could serve as a promising target to improve CBF due to its strong potency and 
relatively enriched level in the brain. A vasodilator mediator produced by the COX enzyme is 
Prostaglandin E2 (PGE2). In the cerebral microcirculation, PGE2 dilates microvessels in the 
presence of NO and counteracts the vasoconstrictive effect of 20-HETE [27]. Indomethacin is a 
non-selective COX inhibitor and celecoxib is a selective COX-2 inhibitor. In a swine VFCA 
model, both indomethacin and celecoxib significantly decreased PGE2 level and attenuated 
increased regional CBF at 30min post ROSC [148]. The blood flow to the heart was also reduced 
with decreased percentage of ejection fraction after indomethacin and celecoxib pre-treatment, 
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which indicates the deleterious effect in the heart post-CA. Selective inhibition of COX-2 have 
been associated with adverse cardiovascular effects including hypertension and stroke [157]. One 
potential mechanism of COX-2 adverse effects is via the shunting of AA to the formation of 
other metabolites upon potent COX-2 inhibition [158]. Based on this putative mechanism, any 
evaluation of future inhibitors of AA metabolism should include assessment of metabolite 
shunting and potential downstream adverse effects. 
It is very common that two fatty acids produced from the same precursor exert opposite 
vascular effects. For example, vasodilatory EETs and vasoconstrictive 20-HETE are metabolized 
from AA by CYP450. Vasodilatory agents, either depressing vasoconstrictive fatty acids, or 
enhancing vasodilatory fatty acids, should be synthesized with high selectivity to prevent 
unwanted interactions.  
2.3.6 Anesthetics 
Anesthetics, acting on ion channels, can affect CBF by interfering with vascular tone. Ion 
channels on the smooth muscle cell membranes are critical to maintain active potential and 
normal basal vascular tone. At least 4 different types of K+ channels, 1 to 2 types of voltage-
gated Ca2+ channels, more than two types of Cl− channels, store-operated Ca2+ channels, and 
stretch-activated cation channels in the smooth muscle cell membranes mediate the effects of 
anesthetics [159].  Bupivacaine is a sodium channel blocker with a biphasic vascular effect. At 
low doses, bupivacaine causes vasoconstriction while at clinical doses, bupivacaine is 
vasodilatory [122]. Li et al. observed normalized early hyperemia and later hypoperfusion with 
bupivacaine infusion in a four-vessel-occlusion rat mode [160]. Thiopental is a barbiturate 
which binds to GABA channel and decreases neuronal activity. Infusion of thiopental increases 
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MAP, reduces oxygen consumption and cardiac output[161]. Controversy exists regarding to the 
efficacy of thiopental after global ischemia. Nemoto, et al. found that  infusion of thiopental at 
90 mg/kg over an hour did not improve brain oxygenation in a neck tourniquet model of global 
ischemia [162]. Similarly, no significant alterations in efficacy were observed with repeated 
dosed thiopental in an asphxial CA canine model [163]. Conversely, Kofke et al. reported 
improved metabolism profile, regional and total CBF after thiopental infusion at 90 mg/kg 
initiated at 5 min post-ischemia in monkeys.[164] Ebmeyer, also observed a mitigation effect of 
thiopental in addition to hypothermia in a 12.5 min VFCA canine model[28]. Desflurane is 
suggested to activate GABA channel, block K+ channel and L-type Ca²⁺ channel[165]. An earlier 
study indicated that desflurane increases heart rate and decreases both MAP and CVR[166]. 
However, Loepke et al. observed that desflurane improved neurological outcome independent 
from a CBF effect in a pediatric piglet CA model [167]. Methyl isobutyl amiloride (MIA) 
although not an anesthetic agent, also affects ion channels. MIA inhibits the Na+/H+ antiporter on 
the membrane and attenuate intracellular alkalosis to prevent neuronal death[168].  In a rat 
model of CA induced by KCl, CBF, rats receiving MIA decreased to ~25% of baseline in all 
brain regions after reperfusion, even lower than rats received vehicle[169]. The uniformly 
reduced CBF could be due to lower pH in the systemic circulation which can lead to 
vasoconstriction. Overall, given current evidence, most anesthetics are not preferred agents to 
increase CBF after CA. First, the efficacy of the anesthetics to improve neurological outcome 
remains to be validated. Second, the observed improvement in outcome could be attributed more 
to flow-independent factors such as metabolism or temperature, rather than CBF itself. Third, the 
long-term exposure under anesthetics could introduce deleterious effects such as hypotension or 
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neurotoxicity. Since anesthetics are used in almost all CA animal models, it is very important to 
consider their effects during CBF assessments.   
2.4 THROMBOLYTIC THERAPIES 
 
Figure 2.2 thrombolytic therapies and their roles in coagulation cascade 
By thrombolytic therapies we refer here to agents which participates in the cascades of 
coagulation, platelet aggregation and fibrinolysis (Figure 2.2). This class of therapies are aimed 
to prevent/degrade the microthrombi formed during or after global ischemia, reduce CVR and 
improve CBF (Eq.1).  
The cerebral microcirculation is impaired after global ischemia, especially the blockade 
of microcirculatory flow. This phenomenon is  firstly described as “no-reflow phenomenon” by 
Ames at al. in 1968, where cortical capillaries failed to be reperfused after global ischemia in 
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rabbits [170]. Similar observations were made afterwards by other investigators [171-173]. 
Patients resuscitated from CA have increased systemic coagulation which could lead to 
microcirculation obstruction [21, 174, 175]. Increased coagulation after CA in the setting of 
unchanged fibrinolytsisc is thought to contribute to the formation of thrombi and block the 
microcirculatory flow.  
2.4.1 Therapies Target on Coagulation Cascade  
Antithrombin is an endogenous protein which prevents the clot formation by inactivation of 
multiple clotting factors, such as Xa and IIa[176]. Heparin and enoxaparin activate  
antithrombin and accelerate the binding of antithrombin-thrombin complex by 2000-4000 fold 
[177]. Human activated protein C (hAPC) is an endogenous anticoagulant acting by degrading 
the cofactors Va and VIIIa [178]. hAPC also possesses anti-inflammation properties by 
modulating cytokine production. The administration of heparin at resuscitation substantially 
decreased the no-reflow region in the forebrain (defined as absence of microvascular filling) to 
7% compared with 28% in the untreated rats after 15 minutes CA [179]. Enoxaparin pre-
treatment but not post-treatment improved post-CA microcirculatory perfusion mitigated the no-
reflow, shortened hypoperfusion duration and increased perfusion ~50% [180]. However, 
injection of antithrombin after CPR did not affect CBF nor oxygen extraction post ROSC [181]. 
High dose of hAPC infusion after reperfusion also failed to influence cortical CBF or reduce 
neuron loss after 14 min global ischemia [182]. These results suggest that these agents might not 
be effective post-insult due to their mechanism of action of preventing thrombin complex 
formation. If the thrombin complex is already formed during ischemia, this class of agents may 
have limited effects in reducing CVR post-treatment.  
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2.4.2 Therapies Targeting the Platelet Aggregation Cascade 
Agents that target the platelet aggregation and affect CBF include aspirin, vapiprost, and 
pentoxifylline. Aspirin is a clinically used non-selective COX inhibitor. Low dose of aspirin 
prevents platelet aggregation by inhibition of COX1, reducing formation of thromboxane A2 
(TXA2) [183]. Treatment with aspirin prior to ischemia almost completely prevented 
hypoperfusion in a four-vessel occlusion rat model [184]. Vapiprost is a specific thromboxane 
A2-receptor antagonist. When vapiprost was dosed prior to cardiopulmonary bypass, CBF was 
found 64.3% of baseline compare with 40.2% of baseline in control group [181]. The cerebral 
oxygen metabolism is also improved to 80.1% compared with 50.0% in the control group. 
Pentoxifylline is a methylxanthine derivative which can decrease plasma and whole blood 
viscosity, increase erythrocyte deformability and prevent platelet aggregation [185]. When 
infused prior to CA, pentoxifylline maintained CBF similar to baseline in a feline VFCA model 
from 5-180 min ROSC while in the control group CBF was reduced to ~50% baseline [186]. The 
improved histological and neurological outcome in another four-vessel-occlusion rat model also 
suggests the benefit of pentoxifylline pre-treatment with improved microcirculatory flow [187]. 
Similar to agents targeting on the coagulation cascade, agents targeting on platelet aggregation 
also requires pre-treatment which limits their application in enhancing microcirculatory flow in 
the post-resuscitation phase.   
2.4.3 Therapies Targeted on Fibrinolytic Cascade 
Urokinase, recombinant tissue type plasminogen activator (rt-PA) and streptokinase 
activate plasminogen and lead to downstream fibrinolytic effect (Figure 2.2). Guo, et al. 
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performed CBF assessment using dual-slice spiral CT and found rabbits receiving urokinase 
infusion at resuscitation had ~16% higher CBF and ~25% greater cerebral blood volume 
compared to rabbits received vehicle treatment in an asphyxial CA model [188]. The 
administration of t-PA at resuscitation substantially reduced the no-reflow areas and 
homogenous microcirculatory flow post-CA in a 15min feline CA model [189]. An earlier study 
by Lin, et al. reported that streptokinase increased CBF which persisted over 3 hours in the grey 
matter and hippocampus in dogs subjected to 12-16 min CA [180]. A recent study by Spinelli, et 
al. demonstrated improved cardiac resuscitability, attenuated ICP and brain edema in a porcine 
model of prolonged CA [190]. Interestingly, an antifibrinolytic agent aprotinin also improved 
carotid blood flow and CBF after resuscitation, but the effect was mainly attributed to the 
endothelium-mediated vasodilation[191]. Compared with therapies targeting the coagulation 
cascade and platelet aggregation cascade, fibrinolytic agents appeared to be more applicable in 
post-resuscitation treatment. Detailed characterization of fibrinolytic agents is necessary to 
demonstrate their potency, optimal dosing time and long-term benefit for outcome assessment.  
Thrombolytic therapies are promising agents to improve CBF especially advantageous in 
the restoration of microcirculatory flow. Fibrinolytic agents appear to be more suitable for post-
resuscitation treatment compared with agents that target coagulation cascade and platelet 
aggregation cascade. One potential deleterious effect for thrombolytic therapies is the bleeding 
risk. However, multiple clinical studies have shown that thrombolytic therapy after CA is 
associated with improved neurological outcome in patients without increased bleeding risks 
[192-195]. Based on this evidence, future clinical trials to evaluate the safety and efficacy of 
such agents on long- and short-term outcomes are necessary to clearly identify the potential 
clinical utility of these drugs in CA patients.   
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2.5 HEMODYNAMIC THERAPIES 
Hemodynamic therapies are aimed at restoring the systemic homeostasis including the 
hematocrit, oxygen, glucose, pH, volume and osmolarity. Stable homeostasis is essential to 
restore CBF post-CA because blood component can determine viscosity, which is inversely 
related to CBF. (Eq.3) In addition, cardiac output changes in compensation to blood volume 
expansion, which also affect perfusion pressure and CBF. (Eq.2) Increased osmolarity reduces 
brain edema and ICP, which favorably affects CBF. (Eq.2) It is worthy to note that intravenous 
administration of almost all agents alters homeostasis due to various solvents which can affect 
hemodynamics and CBF as well. 
2.5.1 Hematocrit Management 
The normal hematocrit level is similar between human and rodents, ranging from 35 to 52% 
[196]. Hematocrit levels post resuscitation vary between different insults. Proper hematocrit 
level is critical to maintain perfusion pressure and oxygen delivery; however, lower hematocrit 
has been associated with higher CBF after resuscitation. Sakamoto et al. showed that piglets with 
25 or 30% hematocrit by total blood infusion post-resuscitation had higher MAP but lower CBF 
compared with piglets with lower hematocrit (10 or 15%)[197]. This suggests that total blood 
infusion leads to increased CVR which could be attributed to higher blood viscosity or even 
formation of microthrombi during infusion. Halstead et al. also demonstrated in pigs that 
hematocrit of 31% by whole blood transfusion leads to ~20-40% lower CBF but superior 
outcome compared with hematocrit of 20% undergoing cardiopulmonary bypass [198]. Increased 
oxygen delivery could attribute to the better outcome observed in high hematocrit group. Since 
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hematocrit is inversely related to CBF, it is important to take both into consideration in the post-
resuscitation phase.  
2.5.2 Hemodilution Agents 
Hemodilution leads to volume expansion which has been generally associated with higher CBF 
and improved microcirculatory flow in CA models [198, 199]. The potential mechanisms are 
reduced viscosity and increased perfusion pressure, assuming cardiac output increases to 
compensate expanded volume load. However, different substitute fluids affect CBF and 
metabolism after resuscitation. Liu, et al. found that Tris buffer and sodium bicarbonate 
enhanced CBF by ~50% without an effect on CPP or CePP in a 5 min VFCA piglet model 
compared with saline control[200]. Their result indicated that alkaline buffer infusion reduces 
CVR due to mitigation of cerebral acidosis, which is well-known to cause vasoconstriction[201]. 
Leonov, et al. pointed out that hemodilution with plasma substitute indeed increased CBF and 
generated homogeneous perfusion 1-4 hours after VFCA, however, the oxygen delivery 
remained unchanged, offset by the lower oxygen level[202]. This result suggests that 
hemodilution with oxygen carriers such as artificial hemoglobin can be promising. In fact, 
clinical study also suggests that higher hemoglobin levels were associated with better 
neurological outcome in out-of-hospital CA patients [203]. However, two animal studies infused 
hemoglobin or hemoglobin conjugates but found different results. In a swine VFCA model, 
infusing diaspirin cross-linked hemoglobin increased CePP [204], while the infusion of 
liposome-encapsulated hemoglobin did not increase hippocampal blood flow in rats after four-
vessel occlusion [205]. Hemodilution can serve as a potential strategy to increase CBF, 
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especially with benefit in microcirculatory flow. However, the reduced oxygen level in the 
diluted plasma should be adjusted to prevent tissue hypoxia. 
2.5.3 Osmolar Therapies 
Brain edema is an inevitable consequence under ischemic conditions such as CA [206]. The 
mechanism of edema formation involves dysfunction of various ion channels, water channels 
and receptors on the blood-brain-barrier. Edema increases ICP which compromises CBF. 
Osmolar therapies are directed to resolve brain tissue edema, decrease ICP and increase CBF 
post-CA. Hypertonic solution with more concentrated NaCl and large molecules such as dextran 
or starch are often used to increase osmolarity. Hypertonic solution, either by infusion or single 
injection, increases CBF in both VF and asphyxial CA models [207-209]. In an 8 min VFCA 
model, pigs that received hypertonic-isooncotic saline (7.5% NaCl with 6% hydroxy ethyl 
starch) infusion during CPR had ~50% higher CBF and sustained for 240 min ROSC compared 
to pigs received normal saline[210]. The improved CBF was observed in multiple brain regions 
including cortex, basal ganglia, hippocampus and cerebellum. Noppens, et al. administered a 
single dose of hypertonic saline hydroxyethyl starch (7.2% NaCl, 6% hydroxyethyl starch) after 
9 min asphyixal CA and found accentuated local CBF[208]. In addition, hypertonic solution also 
improves cerebral microcirculatory flow and reduces “no-reflow phenomenon”. Fischer and 
Hossmann stated that infusion of hypertonic hydroxyethyl starch solution (7.5% NaCl/6% 
hydroxyethyl starch) reduced no-reflow area from 28% to 15% in in the forebrain in a 15 min 
VFCA model [211]. Although the result of CBF improvement is promising, whether hypertonic 
solution improves neurological outcome or survival after CA remains to be demonstrated.  It was 
proposed that hypertonic solution alone is not enough to reverse the severe brain injury post-CA. 
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Wallisch et al. demonstrated that aquaporin-4 inhibitor AER-271 ameliorated early cerebral 
edema and early neurological deficit in a pediatric asphyxial CA rat model [212]. Their results 
suggest aquaporin as a promising target post-CA. Combination therapy using hypertonic solution 
as a solvent is a promising strategy.  
2.6 ANTIOXIDANT AND ANTI-INFLAMMATION THERAPIES 
The ischemic and reperfusion injury underlies the pathophysiology of post-CA brain injury. The 
inflammatory factors, cytokines, superoxide and other reactive oxygen species (ROS) generated 
in this process further exacerbate the neuronal injury [211]. To alleviate the detrimental effects 
of these substances, various antioxidant and anti-inflammatory agents have been evaluated as 
approaches to improve outcome. Although increasing CBF is not the primary goal for these 
agents, secreted inflammatory factors could result in higher blood viscosity and compromise 
CBF. On the other hand, inflammatory factors and cytokines can also stimulate coagulation 
cascade, further blockade microcirculatory flow and decrease CBF.  
Although a wide range of antioxidants have been used in global ischemia models, only a 
few of agents are investigated with CBF assessment. N-acetylcysteine (NAC) and alpha-
phenyl-tert -butyl nitrone (PBN) are both free radical scavengers. Continuous infusion of NAC 
in a neonatal hypoxia-ischemia model was reported to improve cerebral perfusion with 
increased carotid flow and decreased vascular resistance [213]. Pre-treatment with PBN in a 
pediatric cardiopulmonary bypass model also restored global CBF to 78% of baseline compared 
with 52% in the vehicle group [214]. However, neither agents were assessed in CA models with 
CBF measurement. Deferoxamine and U74006F are both inhibitors for lipid peroxidation with 
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different effect on CBF. Deferoxamine administrated 5min prior to resuscitation increased 
cerebral perfusion in hippocampus, thalamus, hypothalamus, and amygdala, but not in cortex in 
rats undergoing prolonged CA induced by esmolol and vecuronium[215].  In a 12.5 min VFCA 
canine model, U74006F given after reperfusion showed no increase of cerebral perfusion in any 
brain region [216]. Polynitroxyl albumin (PNA) exerts antioxidant properties by decreasing 
oxidative and nitrative stress. When PNA was dosed in pediatric rats resuscitated from 9 min 
asphyxial CA, attenuated early hyperemia was observed using MRI but no effect was observed 
with hypoperfusion [183] Attenuation of hyperemia with PNA was associated with improved 
neurological outcomes, suggesting that hyperemia might be detrimental. There is no clear pattern 
to describe the effect of antioxidants on CBF after CA. More often, the mechanism of observed 
changes remains to be clarified. 
Methylprednisolone is a glucocorticoid often used to suppress inflammatory responses. 
The effect of methylprednisolone on CBF is controversial. Langley, et al. reported that 
pretreatment with methylprednisolone increased global and regional CBF after hypothermic CA 
using radio-labelled microsphere [13]. Conflicting evidence is provided by Schubert, et al. who 
showed no protective effect of methylprednisolone pre-treatment in neither cerebral perfusion 
nor neuronal injury in a neonatal piglet model [217]. CBF change after other anti-inflammatory 
agents is still under investigation. Similar to antioxidants, there is no obvious pattern to 
characterize CBF alterations after anti-inflammatory therapies.  
In most studies, both antioxidant and anti-inflammation therapies were used as pre-
treatment. Although antioxidant and anti-inflammation therapies are mostly targeted on oxidative 
stress and neuronal injury which does not manifest until hours or days after resuscitation, these 
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therapies should be initiated in the early phase of post-resuscitation or in combination with other 
agents to mitigate oxidative stress.  
2.7 COMBINATION THERAPIES 
To synergize the effect of increasing CBF or alleviate the deleterious effect of a specific agent, 
combination therapy has been investigated in animal studies as a potential strategy. For example, 
Epi has been used in combination with vasopressin to improve CBF and outcome post-CA[103, 
218]. Compared with Epi used alone, the combination therapy similarly restored spontaneous 
circulation and survival rate but with significantly less neurological deficit [103, 219].  
Synergistic effects have also been reported when combining Epi and vasopressin with more 
sustained and higher cerebral perfusion [219-221], although lower cerebral perfusion was also 
reported[222, 223]. A more recent study by Halvorsen, et al. reported vasopressin dosed alone at 
resuscitation produced 36% higher cortical CBF but similar CPP compared with Epi and 
vasopressin[100]. Benefit was also reported with another combination with Epi, vasopressin and 
nitroglycerin with higher CBF and better neurological outcome compared with Epi alone [101, 
103, 223]. To further establish the superior effect of these combinations, more detailed 
evaluation is needed to address benefit in long-term outcome.   
Some studies combined antioxidants such as deferoxamine and superoxide dismutase and 
found restored CBF post-CA [101, 224]. Another study combined streptokinase and dextran and 
reported increased CBF in the grey matter and hippocampus [225]. In fact, agents such as 
isoflurane, heparin, methylprednisolone which could affect CBF are also used as part of the 
experiment protocol. It is very important to design appropriate control group to minimize 
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confounding variables such as anesthetics or thrombolytics. When interpreting results, it is 
equally important to take these factors into consideration and prevent overinterpretation.   
2.8 DISCUSSION AND CONCLUSION 
 
To provide a better understanding of therapeutic effect on CBF post-CA, we created a 
comprehensive search strategy for existing literature and categorized the pharmacological 
therapies into flow promotion, vasodilatory, thrombolytic, hemodynamic, antioxidant and anti-
inflammatory therapies with their effect on CBF post-CA summarized in previous sections. 
Overall, we believe that flow promotion and vasodilatory therapies which directly targeted at 
CBF are promising agents to improve CBF post-CA. Future studies should further evaluate their 
detailed effect on cerebral microcirculation and the long-term outcome assessments.   The effect 
of other therapies such as hemodynamic, antioxidant and anti-inflammatory therapies, is indirect 
and less potent on CBF improvement post-CA. These agents could serve as a part of combination 
therapy to maximize the effect of CBF restoration and off-set the potential adverse effects of 
other agents.  
We identified several important research areas during literature review. The first research 
area is the heterogenous global ischemia models used in the literature. The CBF alterations after 
CA differs by species, insult type and duration and even animal ages. Although a classical early 
hyper-perfusion and secondary hypoperfusion was observed in most animal studies, several 
studies revealed the temporal and regional variations of CBF in different animal models [8, 190]. 
Given the different pathophysiology of CA, such as VF versus asphyixal, pediatric vs adult, the 
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different CBF patterns could deviate the interpretation of treatment effect. As a result, the same 
treatment could produce beneficial or detrimental effect depending on differences in the model 
selected. At the same time, there is a general need for both randomization and blinding of 
preclinical studies to increase the overall rigor for preclinical CA research.  Future studies that 
focus on model specific mechanisms of CA alterations as they relate to known changes in 
patients will aid in both the identification of individualized therapeutic approaches and 
translatability of preclinical findings.  
Another important area for future research is in the development and validation of novel 
methods for high resolution CBF assessment in both the preclinical and clinical setting.   We 
noticed different methodologies utilized for CBF assessment (Appendix III). Each methodology 
has its own strengths and limitations as reviewed previously [7, 9]. The advanced resolution and 
depth of imaging provide more detailed assessments which is not captured previously.  
Dose regimen is another significant area of research which is often underestimated in 
animal studies. Most pharmacological agents follow a positive dose-response relationship for 
efficacy as well as adverse effects. Higher or more frequent dose regimen often enhances its 
pharmacological efficacy but also magnifies unwanted adverse effects. Therefore, a thorough 
dose-finding study is necessary to optimize efficacy and avoid adverse effect. More importantly, 
the timing for dosing initiation and ending is critical to produce desired pharmacological effect. 
For example, Epi is the most extensively investigated agent in CA studies compared with others. 
The desired vasoconstriction mediated by α-ARs is essential for shorter resuscitation time, 
however, prolonged α-adrenergic effect will constrict cerebral artery and increase CVR. At the 
same time, β-adrenergic effect early is also beneficial by relaxation of trachea smooth muscle 
and enable better ventilation. Prolonged β-adrenergic effect will increase oxygen consumption in 
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the heart and exacerbate ischemia. The early flow over shooting can generate neuronal toxic 
ROS which hopefully could be reversed by antioxidant treatment. The vessel dilators especially 
dilator for small artery could mitigate or prevent hypoperfusion within a given concentration 
range. Taken together, we believe that a combination or sequential therapies might be beneficial 
to target multiple mechanisms of brain injury post-CA and offset each other’s adverse effect 
(Figure 2.3). Detailed characterizations of individual agent, including the dose regimen and 
interval, should proceed the combination or sequential therapies.  
Long-term outcome assessment is an essential piece of evidence but remains missing for 
some therapies. Post-CA brain injury is a complicated pathophysiology process. Although CBF 
alteration is critical to enable sufficient oxygen and nutrients delivery, it is also important to 
monitor other aspects such as brain metabolism to avoid deleterious effect. Most importantly, 
multiple outcome assessments should be performed to determine long-term efficacy. 
Last but not least, the evaluation of cerebral microcirculatory is of great significance. 
Microcirculatory flow is the determinant of oxygen delivery and substances exchange. 
Apparently increased CBF cannot represent better microcirculation due to possible shunt flow. 
Recent studies also emphasize the significance of cerebral microcirculation in CBF regulation 
after ischemia [148, 226, 227]. The cerebral microcirculatory evaluation of different 
pharmacological agents will provide convincing evidence to support or against their effects on 
CBF and outcome post-CA. Novel mechanisms of neuroprotection could also be revealed for 
existing therapies. 
In conclusion, we reviewed pharmacological agents in different categories targeted on 
CBF restoration after CA. Each category possesses a different mechanism while overlapping 
mechanisms are also suggested.  Some agents such as flow promotion agents are better 
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characterized with the existence of conflicting evidences. Further studies are warranted to 
confirm the efficacy and avoid potential adverse effect on CBF and outcome after CA. 
 
 
Figure 2.3 Proposed schematic sequential treatment to improve CBF post-CA 
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3.0  CHARACTERIZATION OF CEREBRAL MICROCIRCULATION AFTER 
















[Li L, et al.  J Cereb Blood Flow Metab.2017] 
 45 
3.1 INTRODUCTION 
CBF impairment have served as a therapeutic target for improvement of neurological function 
after CA, especially the cerebral hypoperfusion in the initial minutes to hours post-CA 
contributes to the overall ischemic injury, as described in animal models [8, 203].   However, the 
cerebral microcirculation post-CA in vivo remains to be characterized, especially the alterations 
of various types of vessels, the red blood cell (RBC) flow and plasma flow in the capillaries.  In 
this section, we sought to establish a scaffold to assess microvascular disturbances after pediatric 
asphyixal CA.   
3.1.1 Epidemiology of Pediatric CA  
Cardiac arrest (CA) is a significant cause of mortality in the pediatric population.   
Approximately 16,000 pediatric patients suffer from CA every year in the United States, 
accounting for up to one quarter of all pediatric mortalities [228].  Thirty-five percent of the 
surviving patients at discharge have unfavorable neurological outcome [229].   To date, no 
pharmacological therapy has demonstrated neuroprotective benefit in the treatment of post-CA 
brain injury. 
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3.1.2 Previous Studies about CBF and Cerebral Microcirculation Post-CA 
Cerebral hypoperfusion in the initial minutes to hours post-CA contributes to the overall 
ischemic injury, as described in animal models [8, 203].   Previously we established a clinically 
relevant pediatric asphyxial CA model in rats [230].   We noted marked regional and temporal 
variation in CBF characterized using arterial spin label magnetic resonance imaging (ASL-MRI) 
[8].   Cortical hypoperfusion was observed 30-120 min after resuscitation and prolonged cortical 
hypoperfusion was associated with poor long-term behavioral outcome.   Subsequently, we 
reported cortical tissue hypoxia, using brain tissue oxygen (PbO2) monitoring, which regionally 
and temporally mimicked the CBF decrement [231].   While the presence of post-CA 
hypoperfusion is well established, the pathophysiological underpinnings of the cortical 
hypoperfusion post-CA have not been completely elucidated or detailed at the microcirculation 
level.  A thorough understanding of the status of the cerebral microcirculation early after CA is 
essential for the development of CBF targeted therapies.   
3.1.3 Role of Cerebral Microvasculature in Regulating CBF 
Cerebral vasoconstriction represents an important microvascular disturbance postulated to cause 
post-ischemic hypoperfusion, as cerebral microvessels play a key role in regulating CBF and 
contribute significantly to cerebral vascular resistance [148, 232].   Various mediators of 
vasoconstriction such as thromboxane, calcium, endothelin (ET), or reactive oxygen species, 
have been targeted experimentally and improved post-resuscitation CBF [77, 233].   In our 
model, inhibition of 20-Hydroxyeicosatetraenoic acid (20-HETE) formation, a vascoconstrictor 
produced in the cerebral microcirculation, improved neurological outcome [27].   Ristagno et al.  
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suggested that microcirulatory disturbances post resuscitation after experimental CA in adult 
pigs contribute to cortical hypoxia, and suggested a possible contribution of epinephrine [47].   
However, there is limited understanding of cerebral microcirculation and RBC flow post-CA, 
especially at the level of pial vessels, penetrating vessels, and capillaries.    
3.1.4 No-reflow Phenomenon 
The no-reflow phenomenon was first described histologically in a global ischemia model in 1968 
[171].   Rabbits subjected to ischemia had incomplete capillary filling upon reperfusion and 
developed occlusive lesions at the particle size of red blood cells (RBCs) in the cerebrum.   
Subsequent studies questioned the existence of the no-reflow phenomenon—suggesting that it 
may have resulted from an artifact of inadequate perfusion pressure in the experimental system 
used [234, 235].   However, others suggested that it can develop, and may result from astrocyte 
swelling, platelet and leukocyte adherence, increased blood viscosity, and/or post-insult 
hypotension, among other mechanisms [236, 237].   The no-reflow phenomenon has yet to be 
characterized in vivo after CA.   
3.1.5 Hypothesis and Objectives 
Two major mechanisms have been identified to date that contribute to decreased CBF post-CA: 
intravascular stasis, also known as the no-reflow phenomenon, and vasoconstriction.   These 
pathophysiological processes have been largely characterized ex vivo using histological methods 
or have been ascertained from experiments using pharmacological manipulations.  Therefore, we 
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hypothesize that microvessel constriction and disturbances of capillary RBC flow lead to cortical 
hypoperfusion post-CA.    
3.2 METHODS 
3.2.1 Animals  
This study was performed in accordance with Guide for the Care and Use of Laboratory Animals 
(8th Ed), published by National Research Council and approved by the Institutional Animal Care 
and Use Committee at the University of Pittsburgh.   All experiments were reported according to 
the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.  Male Sprague-
Dawley, post-natal day (PND) 16-18 rats (30-45 g) were used in this study.  Four cohorts of rats 
were used for the measurement of microvascular diameter (n=8), assessment of capillary RBC 
flow (n=12), RBC velocity and density (n=8), and cortical plasma mean transit time (MTT) 
(Sham and CA group, n=5/group). 
3.2.2 Surgical Preparation and Asphyxial CA 
We utilized an established pediatric asphyxial CA rat model [230] with slight modifications for 
CBF assessment [8].   Rats were initially anesthetized via inhalation of 3% isoflurane in N2O and 
oxygen (50:50), administered via a nasal cone.   The trachea was then intubated, mechanical 
ventilation was initiated, and isoflurane was reduced to 2.5%.   After the placement of femoral 
arterial and venous catheters, to reduce the effect of isoflurane on CBF, we discontinued the 
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isoflurane and administered fentanyl intravenously at a constant rate of 50 μg/kg/h for the entire 
duration of the experiment.   Neuromuscular blockade using vecuronium was administered 
intravenously at a rate of 5 mg/kg/h.   Body temperature was maintained at 37℃ with a heating 
pad.  The experiment settings are illustrated in Figure 3.1.   
Figure 3.1 Experiment settings for in-vivo microscopy 
 
To prepare for in vivo microscopy, the rat was placed prone on the surgical table and the 
head was stabilized in a stereotactic frame.   The skull was then exposed through a midline scalp 
incision.   A circular craniotomy of 3-4 mm was performed over the sensory-motor cortex.   
After removing the bone, an optical chamber was created.   A solution of 1% agarose in normal 
saline was applied to the intact dura.   A coverslip of 5 mm diameter was applied over the 
agarose and was secured with tissue glue and dental cement.    
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Rats were subjected to 9 min asphyxial CA, which produces cortical hypoperfusion as 
assessed by ASL-MRI [8].   The FiO2 was reduced to 0.21 (room air) for 1 min before asphyxia 
to prevent hyperoxygenation.  CA was induced by disconnecting the tracheal tube from the 
ventilator for 9 min after neuromuscular blockade.   Resuscitation was started by reconnecting 
the ventilator at a FiO2 of 1.0 and was followed by the administration of epinephrine (0.005 
mg/kg, iv), sodium bicarbonate (1 mEq/kg, iv), and manual chest compressions until return of 
spontaneous circulation (ROSC).   A FiO2 of 1.0 was maintained until the end of the experiment.   
3.2.3 Cerebrovascular Imaging Using Multi-Photon Microscopy  
To assess the microcirculation, we used in vivo multiphoton microscopy.  A Nikon A1R MP 
microscope was configured with the Nikon Ni-E (Nikon Instruments; Tokyo, Japan) upright 
motorized system.   The microscope was equipped with a Chameleon Laser Vision (Coherent, 
Inc; CA, USA), an APO LWD 25× water immersion objective with 1.1 NA, a high-speed (30 
frames/second) resonant scanning mode and a galvano-mode scanning suitable for linescanning 
acquisitions.   The Nano-Drive system was used to acquire fine high-speed control of z-plane 
selection.   The fluorescence detection unit of the microscope consisted of four detectors (photo 
multiplying tubes).   We used detector 2 for FITC 525 / 50 nm (green channel).   The microscope 
components including the laser, stage, resonant scanning head, detectors and acquisition were 
controlled using NIS Elements software (Nikon). 
To delineate the vasculature, we administered Fluorescein isothiocyanate–dextran (FITC; 
Sigma, wt 2,000,000) 3% (w/v) 0.1mL at baseline.   Additional doses of FITC were given as 
needed to maintain adequate delineation of the microvasculature.  The specific sequence of FITC 
administration for the MTT experiment is detailed below.   Post-acquisition image processing 
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was achieved using NIS Elements and MATLAB (R2015a, The MathWorks, Inc.  Natick, 
Massachusetts USA).   The microscope stage was enclosed in a temperature controlled black 
plexiglass chamber, which prevented interference by the ambient light.   We used an excitation 
wavelength of 850 nm and a laser power of 1-2%.    
3.2.4 Assessment of Cerebral Microvessel Diameter 
 
Figure 3.2 A representative 3D image stack of the cortical microvasculature.   The z depth is about 
250 µm. 
Image stacks were acquired at baseline, and at 5, 30 and 60 min post-CA in 8 rats.    The 
following parameters were used:  field view of 512×512 pixels at a resolution of 1µm/ pixel 
using resonant mode, 16 times average.   Cortical microvessels were categorized by size and 
morphology into five types.   Data were collected from 8 rats and 39 pial arterioles, 134 pial 






were identified by their location on the pial layer, and morphologically by their relatively straight 
appearance and fewer branches.   Pial venules were identified as vessels also located on the pia 
surface but with tortuous contours and more branches than the arterioles.   Penetrating arterioles 
and penetrating venules were identified as vessels branching from the parent pial arterioles and 
draining into pial venules, respectively, and perpendicular to the pia.   Capillaries were identified 
as microvessels located in the parenchyma and with diameter of less than 10 µm at baseline 
(Figure 3.2).   For each animal, 3-5 locations with adequate contrast resolution were identified 
within the imaging window at baseline.   The image stacks reached to a depth ranging from 250-
400 µm from the pia.   All the locations were saved in the software such that the system was able 
to automatically obtain imaging stacks at the same location post-CA.   At each location, the 
baseline imaging stacks were set as reference stacks to which post-CA stacks (5, 30 and 60 min 
post-CA) were overlaid in the x-y-z dimensions (Figure 3.3).   The vessel diameters at each time 
point were then quantified from a single location per segment from the maximum projection of 
the aligned image stacks using the Annotation and Measurement function in NIS Element.   The 
accuracy of the measured shape is subject to the point-spread function of the system which is 
roughly 0.29 μm in-plane.   Simulations at this resolution show that under noiseless conditions, 
vessel diameter can be estimated with sub-pixel precision with error <10% for vessels >3um, 
error <7% for vessels >4um, and error <4% for vessels >5um.   Only the vessels with acquired 
data at all four-time points were included.    
3.2.5 Assessment of Capillary RBC flow (No-reflow Phenomenon) 
The live time-series at baseline and post-CA were acquired to assess the presence of RBC flow 
vs.  stasis in the capillaries, defined as microvessels in the parenchyma with diameter of less than 
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10 µm.   With FITC delineating the plasma, RBCs appear as oval negative signals and a size of 
3-6 µm.   The time-series were acquired at the speed of 30 frames/s with resonant mode.   To 
capture the movement of RBCs, 2-3 time-series were identified per animal at baseline and 1-3 
capillaries with adequate contrast were included in each time-series.    The locations for each 
time-series were recorded so that the same capillaries could be repeatedly assessed post-CA.   All 
capillaries captured at baseline had continuous RBC flow.   Absent RBC flow was defined as no 
RBC flow during the time series (15-30 s).   Some capillaries were observed to have stagnant 
RBCs that appeared fixed in place in the vessel, while others did not have any RBCs or RBC 
flow visualized, such that only plasma filled vessels were seen.   A total of 59 capillaries from 12 
rats were evaluated.    
3.2.6 Assessment of Capillary RBC Velocity and Density 
To quantify the capillary RBC velocity and density, the linescan method was applied, as 
previously described [238].   Briefly, a straight section of a capillary with adequate contrast was 
identified at baseline.   The scan path was then placed along the capillary lumen.   In linescan 
mode, the movement of RBCs is detected as an angled streak.   For a known scan speed, the 
velocity of the RBC movement is proportional to the slope of the streak.   Linescans were 
collected at a speed of 1000 lines/s for 10-15s on capillaries at baseline and post-CA.   To 
quantify and compare the effect of CA on RBC velocity, only capillaries with both baseline and 
post-CA reliable measurements were included.   Capillaries with stagnant RBCs flow were not 
included due to unreliable linescan reading.   The RBC velocity was quantified by analyzing the 
angle of RBC streaks in contiguous 150-250 lines using MATLAB.   In total, we measured the 
RBC velocity and density in 39 capillaries from 8 rats at baseline and post-CA.   To assess the 
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effect of anesthesia over time in our preparation on RBC velocity, we also collected 
measurements from 33 capillaries of 4 sham operated rats and found no change in either RBC 
velocity or density during the 60 min measurements (data not shown).    
3.2.7 Assessment of Mean Transit Time of Plasma Through the Cortical 
Microcirculation 
The MTT was assessed to describe the time required for plasma to traverse the cortical 
microcirculation.   A pial artery and adjacent pial vein supply regional cortical blood flow, 
therefore the plasma transit time from the pial artery to the pial vein indicates the plasma flow 
that traverses the cortical capillary bed.  A longer MTT indicates slower capillary plasma flow 
which suggests capillary flow disturbances.   MTT was assessed at baseline and at 30 and 60 min 
after CA or sham surgery (n=5/group) using a previously described method [239, 240].   Briefly, 
a pial artery and an adjacent pial vein were identified in the imaging field (512×512 µm) at 
baseline.   Time-series were recorded at the speed of 30 frames/ second with resonant mode 
during a bolus of FITC dextran (3% w/v, 0.03mL) iv injection at baseline, 30 and 60 min post-
CA.  The time-series were fitted with a median filter and smooth function to reduce the motion 
artifact.   Two regions of interests (ROIs), one on a pial arteriole and the other on a pial venule 
were identified (Figure 3.5B).   The intensity of the fluorescent tracer in the selected ROIs were 
then plotted over time using NIS Element software.   The standard γ function was fit to the 
intensity-time curves in MATLAB (Figure 3.5C).   Time-to-peak (TTP) was defined as the time 
required for intensity change from baseline to the peak in the fit curves for the artery and vein.   
MTT was defined as the difference of TTP between the pial artery and the pial venule ROIs 
(Figure 3.5 C) at each time point.   In addition, to evaluate the MTT for the entire pial vessel 
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network within the imaging field, the TTP for each pixel in the time-series was calculated and 
normalized to the TTP of the arterial ROI.   Image processing was implemented in MATLAB.   
All the post-measurements were normalized to the corresponding baseline values.    
3.2.8 Statistical Analysis 
Descriptive statistics were tabulated to summarize the measurements.  Means and standard error 
of the means (SEM) were presented for the continuous variables.  Data were analyzed by using 
SPSS (IBM Corp.  IBM SPSS Statistics for Windows, Version 24.0.  Armonk, NY: IBM Corp.) 
and figures were generated using Graphpad Prism 6 (GraphPad Software, Inc.  La Jolla, CA, 
USA).  Physiological parameters were tested for time effect within each experiment using 
repeated measurement ANOVA followed by Dunnett’ post-hoc comparison.  For the MTT 
experiments, physiological data were analyzed using repeated measure ANOVA.   Microvessel 
diameters were log transformed to normalize the distribution.  In each type of vessel, we 
analyzed the diameter measurements in a mixed linear model.  In this statistical model, repeated 
measurements for each vessel were nested within vessel number, and vessel numbers were 
nested in each animal.  Similarly, RBC velocity and density were also log transformed and 
analyzed in a mixed linear model.  MTT measurements were normalized to the baseline value for 




3.3.1 Physiological Parameter Summary 
Physiological parameters, including mean arterial pressure (MAP), end-tidal (Et) CO2 and 
temperature, were recorded throughout the experiment.   All physiologic parameters were within 
normal limits at baseline.   All animals included in the study were successfully resuscitated from 
CA and had return of systemic circulation for at least 60 min post-CA.   The physiologic 
parameters for each experimental group are summarized in Table 3.1.   As expected, rats 
subjected to CA had a modest temperature reduction at 5 min post-CA compared to baseline as 
normothermia was not actively maintained during the no-flow period—to mimic clinical CA.   
Also as anticipated, given the resuscitation, for the group in which capillary RBC flow was 
assessed, EtCO2 was lower at 5 and 30 min post-CA, and MAP higher at 5 min post-CA 
compared with baseline.  Similarly, for the group in which MTT was assessed, the CA group had 
lower EtCO2 compared with shams.   No other significant differences were observed in the 
physiological data. 
3.3.2 Assessment of Microvessel Diameter 
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Figure 3.3 Representative images of a pial arteriole, pial venule, penetrating arteriole, penetrating 
venule, and cortical capillary at baseline and post-CA coded with pseudo colors. 
We observed pial arteriolar constriction at 60 min post-CA compared with baseline, indicated by white arrows.  The pial and 
penetrating venule and capillary dilations are visualized at 5 min post-CA and indicated by white triangles. 
 
Figure 3.2 illustrates images of microvessels from one representative rat at baseline.   The 
diameter change post-CA for representative microvessels is illustrated in Figure 3.3.      Vascular 
dynamics post-CA were different in different types of vessels.   The diameter of pial arterioles 
was similar to baseline at 5 min post-CA and decreased at 30 and 60 min post-CA (19.6±1.3, 
19.3±1.2 vs 22.0±1.2µm, 30, 60 min post-CA vs baseline, respectively, p<0.05) (Figure 3.4 A).   
No difference was found in the diameter of penetrating arterioles after CA vs baseline (Figure 
3.4 B).   Capillaries had increased diameter early post-CA at 5 min and returned to baseline value 
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at 30, 60 min post-CA (5.5±0.2 vs 5.0±0.2µm, 5 min post-CA vs baseline, p<0.05) (Figure 3.4 
C).   Penetrating venules had increased diameter at 5 min post-CA and returned to baseline value 
at 30 and 60 min post-CA (20.6±1.2 vs 18.0±1.1µm, 5 min post-CA vs baseline, respectively, 
p<0.001) (Figure 3.4 D).  Similarly, the diameter of pial venules increased at 5 min post-CA and 
returned to baseline at 30 and 60 min post-CA (20.0 ± 1.0 vs 17.2±0.8µm, 5 min post-CA vs 
baseline, p<0.001) (Figure 3.4 E).   
  
 
Figure 3.4 Mircovascular diameter changes post-CA. 
Diameter changes for pial arterioles (A), penetrating arterioles (B), capillaries (C), penetrating venules (D) and pial venules (E).   Post-CA values 
are normalized to pre-CA values for each vessel.   Data were collected from eight post-natal day 16-18 rats at baseline and post CA.  The 
diameters of pial arterioles decreased at 30 and 60 min post CA vs.  baseline (* p<0.05).   The diameters of capillaries increased at 5 min post CA 
compared with bassline (p<0.05).   The diameters of the pial and penetrating venules increased at 5 minutes post-CA (*** p<0.001).    
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3.3.3 RBC Flow (No-reflow Phenomenon)  
We assessed the continuity of RBC flow in the cortical capillaries at baseline and post-CA.   At 
baseline, RBC flow was continuous in all capillary branches (Supplementary video V1).   In 
capillaries, stagnant RBCs were seen early as 5 min post-CA (Figure 3.5 A and supplementary 
video V2).   Stagnant RBCs were observed in several bifurcated branches of a capillary loop 
(Figure 3.5 A), or more often stagnant flow was observed in only one of the branches, while in 
the other branches RBC flow remained continuous (Figure 3.5 B).   Stagnant RBCs appeared to 
be attached to the capillary wall (Supplementary video V2 and V3).    
Among 59 capillary branches from 12 rats with continuous RBC flow at baseline, 25.4% 
of capillaries (15/59) were observed to have no RBC flow at 30 min post CA.  At 60 min post-
CA 13.5% capillaries (8/59) were found with no RBC flow.  Out of the 8 capillaries with no 
RBC flow at 60 min post-CA, 7 capillaries had no RBC flow at 30 min post-CA. 
Overall, no-reflow was captured in 7 out of 12 rats at 30 or 60 min after CA.  In four rats 
the no-reflow was observed at 30 min and was not observed at 60 min in the capillaries studies.  
In two rats no-reflow was observed at both time points, and in one rat it was observed only at 60 
min post-CA.     
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Figure 3.5 Capillary RBC flow after CA. 
Upper panel: Illustration of RBC stasis (no-reflow phenomenon) in representative capillaries in vivo.   Panels A and B represent two 
individual capillaries with stagnant RBCs post-CA from two rats.   Both capillaries were continuously perfused with red blood cells (RBCs) prior 
to CA.   Red arrows indicate the flow direction in every capillary branch.   White arrows indicate stagnant RBCs.   In panel A, RBC flow was 
stagnant in all branches at 5, 30 and 60 min post-CA.   In panel B, RBC flow in the left branch was stagnant at 5, 30 and 60 min post-CA, while 
the RBC flow in the other two branches was continuous.   
 
3.3.4 Assessment of capillary RBC velocity and density  
To quantify the movement of RBCs in the capillaries with continuous RBC flow post-CA, we 
examined the RBC velocity and density using linescan.   Capillaries with stagnant RBCs were 
not included in this evaluation due to the unreliable linescan quantification.   Capillary RBC flow 
was highly heterogeneous at both baseline and post-CA (Figure 3.6 A and B).   No change was 
seen in the capillary RBC velocity at baseline and post-CA (0.62±0.08 and 0.67±0.07 mm/s, 
p=0.195).    RBC density increased post-CA in the perfused capillaries (7.57±0.37 vs 6.50±0.46 
RBC/s, post-CA vs baseline, p<0.05).    
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Figure 3.6 RBC velocity and density in patent capillaries. 
RBCs velocity (A) and density (B) were calculated from capillaries with continuous flow at baseline and post-CA (39 capillaries from 
8 CA rats).   RBC density was increased post-CA compared with baseline.   Each symbol represents a single vessel.   *p<0.05. 
 
3.3.5 Assessment of Capillary Mean Transit Time of Plasma Through the Cortical 
Microcirculation 
Overall MTT increased post-CA compared with sham (200.6±29.2 vs 90.0±9.1%, post-CA vs 
post-sham, p<0.05).   At 30 min post-CA, MTT increased compared to baseline (p<0.001) while 
at 60 min post-CA, MTT showed a non-significant trend towards increase compared to baseline 
(p=0.08) (Figure 3.7 A).   No change in MTT for sham rats was observed at any time points.    
Figure 3.7 B shows the pial vascular network in a representative rat with pial artery and 
pial vein ROIs (white and yellow squares, respectively).   Figure 3.7 C presents intensity-time 
curves at baseline, 30, and 60 min post-CA.   
Prolonged MTT was also observed when the entire pial network was evaluated (Figure 
3.7 D).   In the representative example illustrated, brighter color indicates relatively longer 
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latency compared with arterioles, and the brightness appeared in almost all the branches of pial 
venules.   The most prolonged MTT appeared at 30 min post-CA, and partially recovered at 60 
min post-CA.   
 
 
Figure 3.7 Mean transit time of plasma through cortical microcirculation.    
A.   MTT increased post-CA at 30 and 60 min vs.  sham (* p<0.05).  Each line represents an individual rat, n= 5/group.  B.  The 
cortical pial vasculature of a representative rat: the yellow square represents a region of interest (ROI) on a pial vein, while the white square 
represents a ROI on a pial artery.   The intensity of the fluorescent tracer was repeatedly measured in the same ROIs at baseline, and at 30 and 60 
min post-CA.   C: Intensity-time curves and γ fit curves at baseline, 30, 60 min post-CA (left to right).   MTT increased at 30 and 60min post-CA, 
indicated by the black arrows.   D: The time-to-peak (TPP) for each pixel on the pia layer was calculated and normalized to mean arterial TPP.   
Increased MTT was observed at 30, 60min post-CA in most of the pial veins, indicated by brighter color.
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Table 3.1.   Physiology parameters for each group of rats. 
Experiment 
groups 
 Temperature (℃) EtCO2 (mmHg) MAP (mmHg) 
 N baseline 5min  30min  60min  baseline 5min 30min 60min  baseline 5min  30min  60min 
Diameter 8 37.3±0.3 36.2±0.2# 37.3±0.4 36.8±0.2 35.7±1.9 31.5±1.1 29.7±3.1 27.0±2.4 56.4±3.2 66.1±6.4 52.57±3.5 55.0±3.8 
RBC flow 12 37.1±0.3 35.6±0.2# 36.9±0.3 37.1±0.2 36.3±1.1 30.9±1.2# 28.3±2.0# 29.5±2.1 54.5±3.0 68.5±4.4# 50.7±3.7 51.5±3.7 
RBC velocity 8 37.2±0.4 35.7±0.2# 36.4±0.3 37.2±0.3 36.1±1.0 36.3±2.9 30.1±2.0 32.6±1.6 56.4±4.0 59.0±4.5 55.0±3.2 50.0±4.1 
MTT (CA) 5 37.9±0.4 35.6±0.3*# 36.7±0.4 37.2±0.5 33.6±2.6* 32.0±2.1* 32.0±3.4* 30.3±2.3* 65.0±2.2 61.0±2.4 59.6±4.8 57.0±9.4 
MTT (Sham) 5 37.6±0.5 37.2±0.4 37.6±0.2 37.4±0.1 36.1±1.6 38.7±2.1 36.4±1.7 37.0±3.7 59.2±1.9 56.3±3.8 56.3±2.4 55.0±4.6 




Using in vivo microscopy, we characterized cortical microcirculatory disturbances during the 
first 60 min after CA in a pediatric rat model of CA and resuscitation.  Immediately after 
resuscitation, brief transient dilation of capillaries and venules is followed by prolonged pial 
arteriolar constriction.  At the capillary level, the microcirculatory disturbances are 
heterogeneous; a no-reflow phenomenon is present in a quarter of capillary branches post-CA, 
while the RBC velocity is maintained in the patent capillary branches, there is a higher density of 
RBCs.  Overall, the time required for plasma to travel from the pial arterioles through capillaries 
and into the pial venules is increased after CA (Figure 3.8).  Our results detail the cortical 
microvascular alterations post-CA in the developing rat brain, and should serve as a platform to 
assess both the impact of standard of care interventions and novel vascular-targeted therapies on 
perfusion after CA.      
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Figure 3.8 A schematic summary of our finding. 
The capillaries are perfused with RBC flow at baseline.  At 5 min post-CA, capillary no-reflow is present in some capillaries, and pial venules 
and penetrating venules are dilated.  At 30, 60 min post-CA, pial arterioles are constricted while the diameter of venules returned to baseline 
level.  No-reflow is present in a fourth of capillaries at 30 min post-CA. 
3.4.1 Pial Arteriolar Constriction  
We observed constriction at the level of the pial arterioles and not penetrating arterioles at 30 and 
60 min after resuscitation, suggesting that pial arterioles are responsible in part for the decreased 
cortical CBF after CA.  Arteriolar smooth muscle plays an important role in regulating local CBF 
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and maintaining blood pressure autoregulation [232, 241].   Under physiological conditions, pial 
arterioles on the surface of the brain are regarded as the major site of flow control, especially 
during functional hyperemia when upstream pial arteriolar dilation was observed away from the 
site of brain activity [242].   According to the Poiseuille's equation, arterial constriction of 10% 
is expected to produce a CBF reduction of ~36%.  The arteriolar constriction observed thus 
correlates with the 30-50% decreased in cortical CBF assessed using ASL-MRI in our model in a 
prior report [8].   Our results are also consistent with previous reports of arteriolar constriction in 
gerbils after bilateral carotid artery occlusion and reperfusion [239].   The pathophysiological 
mechanisms governing post-ischemic arteriolar vasoconstriction are not fully elucidated.   It has 
been suggested that disturbances in the balance of vasoconstrictors and vasodilators are 
responsible for arteriolar vasoconstriction post-CA.   Vasoconstrictive mediators such as ET, 
reactive oxygen species, and some products of arachidonic acid metabolism are increased after 
global or focal ischemia [27, 77].   Vasodilator mediators such as nitric oxide or selected 
metabolites of arachidonic acid are decreased after ischemia and might facilitate vasoconstriction 
[27, 243].   Our observations further support the potential benefit of therapies promoting 
vasodilatation to optimize CBF after CA [244].   Indeed, several vasodilator strategies such as 
use of the calcium channel blockers [127], or thromboxane inhibitors [245] proved beneficial in 
improving CBF and in some instances outcome after CA in preclinical models.   In our model, 
inhibiting the vasoconstrictive eicosanoid 20-HETE improved CBF early after CA, and 
decreased neuronal degeneration and neurological deficits [27].   Similarly, in other models, the 
ET(A) receptor antagonist BQ123 improved functional outcome and CO2 reactivity after CA 
[77] and administration of the vasodilator nitrite improved neurological outcome and was 
accompanied with reduced reactive oxygen species production [243].  A more complete 
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characterization of the effects of therapies targeting arteriolar vasodilation in cortex is warranted 
and supported by our findings.  The impact of these interventions on the observed derangements 
in the microcirculation could provide additional insight to conventional CBF assessments.   
3.4.2 Early Capillary and Venular Dilation 
Capillary and venular dilation was observed at 5 min after resuscitation.   At this early time some 
of the capillaries had evidence of RBC stasis, despite a lack of pial and penetrating arteriolar 
constriction.  The role of capillaries in regulating CBF is controversial.  The dilatation of 
capillaries could represent either a passive compensatory mechanism to accommodate blood 
flow in patent capillaries, or an active process in response to tissue acidosis and/or hypoxia, and 
merits further study.   Hall, et al.  suggest that 84% of CBF regulation occurs at the capillary 
level, and the capillaries responded to whisker-pad stimulation earlier than the arterioles [148].   
Conversely, other studies suggest that arterioles rather than capillaries are responsible for CBF 
regulation [232].   Similarly, we found that the capillary diameter increased only transiently at 5 
min post-CA and returned to baseline afterwards.   At 5 min post-CA, the increased MAP in the 
absence of arteriolar constriction may have produced increased hemodynamic pressure in the 
capillaries and venules, leading to capillary dilation.   The increased MAP could be secondary to 
a transient increase in cardiac output and the hypertensive effect of epinephrine post-
resuscitation if autoregulation is impaired [246], or may be due to a transient increase of blood 
volume secondary to the osmolar effect of bicarbonate administrated at resuscitation.   At 30 and 
60 min post-CA we observed constriction of the pial arterioles with concomitant return of MAP 
to baseline, which could explain the return diameter of capillaries and venules to baseline levels.   
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3.4.3 RBC stasis and No-reflow phenomenon 
We observed RBC stasis in a fourth of the capillary branches.  This observation, referred to as 
the no-reflow phenomenon, was previously described ex-vivo and was suggested as a mechanism 
underlying cerebral hypoperfusion after global ischemia [247].   In a model of CA, the no-reflow 
phenomenon was observed post-CA in 30% of brain regions [173].   Our in-vivo evaluation 
provides specific morphological data regarding the no-reflow phenomenon, supporting its 
existence and further defining its appearance at the microcirculatory level.  Our data suggest that 
individual capillary branches are affected, and flow is diverged from the affected branches 
towards the surrounding capillaries.  Some branches with no RBC flow regain perfusion by 60 
min after CA.  Thrombocyte and leukocyte aggregation, as well as decreased RBC deformability 
post-CA may play a role in the no-reflow phenomenon [248].   Thrombolytic therapy using 
plasminogen activator and heparin reduced the no-reflow post-CA [180] and blood flow 
promotion therapy with hypertension and hemodilution instituted upon resuscitation from CA 
normalized post-resuscitation CBF and improved neurological outcome in dogs [203].   
Pentoxifylline, a hemorheological agent which can reduce RBC deformability, has been shown 
to ameliorate the hypoperfusion post CA [249].   Similarly, we qualitatively observed that RBCs 
appeared to be less deformable after CA.   Given that decreased in RBC deformability has been 
associated with acidosis [250], the change in RBC membrane elasticity in the acidotic milieu 
post-CA might contribute to the RBC stasis.   Additionally, arteriolar constriction may 
exacerbate the no-reflow phenomenon, as arteriolar constriction in a model of focal ischemia was 
thought to contribute to hypoperfusion, thrombosis and distal microvascular occlusions [232].   
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3.4.4 Increased RBC density post-CA 
We observed increased RBC density in the patent capillaries after CA.   The increased density of 
RBC could represent their passive redistribution diverted from the blocked capillaries towards 
patent capillaries, or active recruitment of oxygen carrying RBCs to areas affected by the no-
reflow via an alternative capillary route.   In patent capillaries, RBC velocity was similar to 
baseline.  Obstruction of ~25% of capillaries without an increase in RBC velocity in the 
capillaries that remain patent contributes to the increased plasma MTT.   
3.4.5 Plasma Mean Transit Time post-CA 
The transit time of plasma in the cortex provides an overall assessment of microvascular 
dynamics after CA and integrates the microcirculatory components assessed, including vascular 
diameter, capillary patency, and velocity.  Similar to our data, Crumrine and LaManna calculated 
MTT based on measurements of CBF and cerebral blood volume (CBV) and reported a four-fold 
increased transit time at 30 and 60 min after CA [251].   The peak increase in MTT in our study 
was observed at 30 min post-CA, coinciding with the peak of the capillary obstruction, 
suggesting that the longer duration required for plasma to traverse the capillary bed is secondary 
to the capillary obstructions.   Pial arterial vasoconstriction, along with stasis at the level of 
capillaries likely contribute to increased MTT and together represent the underlying vascular 
mechanism for cortical hypoperfusion observed in our model. 
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3.4.6 Limitations 
We assessed alterations in cerebral microcirculation in a pediatric model of CA in immature rats.   
In pediatric CA asphyxia is the predominant mechanism, in contrast to adult CA where most 
cases are resulted from ventricular fibrillation (VF) [228].   In comparison with VF CA, the 
unique pathophysiology of asphyxial CA includes hypoxia, bradycardia, hypovolemia, 
arrhythmia, acidosis leads to different CBF disturbances post-CA [252], and most likely, distinct 
alterations in cerebral microcirculation.   Indeed, the CBF alterations observed in our model 
using ASL-MRI differ from the adult model of CA, especially at early time points after 
resuscitation, where cortical hyperemia is observed after adult CA [252].   The alterations 
observed in our study might be specific to the pediatric brain, especially in light of recent data 
that unveiled that the vascular response to neuronal stimulation was different in neonatal vs.  
adult rats, specifically functional hyperemia was uncoupled from neuronal activity in developing 
rats from 7 to 13 days postnatally [253].   This difference in the vascular response in pediatric vs.  
adult brain may be explained by myriad processes occurring at the neurovascular unit in the 
developing brain, such as angiogenesis, vascular pruning, and gradual maturation of astrocytes 
until PND 21 [254].   The vast majority of studies of microcirculation in global cerebral ischemia 
or CA used adult models [47], and thus the current characterization of microcirculatory changes 
in a pediatric model is important for the understanding of pediatric specific post-CA 
pathophysiology and ultimately for the development of pediatric specific therapies.   
We observed a modest decrease of temperature at 5 min post-CA compared to baseline 
due to spontaneous cooling during CA.  Clinically the same extent of cooling may not develop 
during CA in humans, due to significantly different body surface area and metabolism rates.  
This is a limitation of the rodent model that may affect vascular changes at early time points (5 
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min).   Sodium bicarbonate was given in this experiment to correct the acidosis post-CA.   This 
could potentially limit the translational significance of the current study.   Post-CA hypocarbia 
may also contribute to the reduced CBF post-CA.   We used male rats in our study, and although 
PND 16-18 is a pre-pubertal age, innate sex differences have been reported: cytotoxicity and 
programmed cell death [255, 256].    Further experiments using female rats are warranted.     
3.5 CONCLUSION 
In conclusion, we characterized in vivo the dynamic changes of the cortical microcirculation in 
an established pediatric CA model that produces cortical hypoperfusion and tissue hypoxia in 
rats.  Our study identifies several vascular-specific targets in the microcirculation to mitigate 
these derangements.  Characterization of the effects of both standard post-resuscitation therapies 
along with novel approaches on the microcirculation after pediatric CA could optimize post-
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4.1 INTRODUCTION 
4.1.1 Arachidonic Acid Metabolism Pathway by Cytochrome P450 Enzyme 
Metabolites of arachidonic acid (AA) have long been recognized to play a pivotal role in 
multiple pathophysiologic processes [257, 258].  The bioactivation of AA by cytochrome P450 
to hydroxylated and epoxygenated metabolites has been implicated in inflammation, 
hypertension, cancer, and neurological disorders [146, 259, 260]. Under pathophysiological 
conditions, AA is released from phospholipids and quickly metabolized by cytochrome P450 
enzymes into hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids, which are vasoactive 
fatty acids that regulate blood flow in the renal, cerebral, coronary and pulmonary circulations 
[261-263].  
 
4.1.2 20-hydroxyeicosatetraenoic acid (20-HETE) Inhibition Serves as a Promising 
Target for Neurovascular Diseases 
Terminal hydroxylation of AA by CYP4A/4F subfamilies produces 20-hydroxyeicosatetraenoic 
acid (20-HETE) which is a potent vasoconstrictor and also involved in apoptosis, 
neuroinflammation and superoxide production pathways  [154-156].   In neurological conditions, 
increased 20-HETE was observed after CA, traumatic brain injury (TBI), intracerebral 
hemorrhage and ischemic stroke [27, 264, 265].   Inhibitors of the CYP4A/4F enzymes reduce 
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20-HETE synthesis and have been shown to be neuroprotective both in vitro and in vivo.   N-
Hydroxy-N'-(4-n-butyl-2-methylphenyl) formamidine (HET0016), a potent CYP4A/4F inhibitor, 
increased cerebral perfusion and improved short-term neurological outcome in an experimental 
pediatric cardiac arrest (CA) model [27].  More recently, direct neuroprotectant effects of 20-
HETE inhibition were described both in vivo and in vitro.  HET0016 treatment was shown to 
exert protective effects on cultured neurons, astrocytes and also hippocampal slices exposed to 
oxygen-glucose deprivation [155, 266, 267].  Neuroprotection after HET0016 treatment was also 
observed in a model of pediatric asphyxial CA in piglets, albeit without a measurable effect on 
cerebral perfusion evaluated by laser doppler [268].  Therefore, 20-HETE formation inhibition 
serves as a potential therapeutic strategy to improve neurological outcome in hypoxic and 
ischemic conditions through dual neuronal- and vascular effects.  The precise mechanism of 20-
HETE action at the level of cerebral microvasculature has not been detailed in vivo.    
3.1.3  
The mechanism of 20-HETE induced vasoconstriction involves the depolarization of 
vascular smooth muscle membrane secondary to blocking the large-conductance Ca2+-activated 
K+-channels [150-152] and stimulation of the L-type Ca2+ channel [90, 153].   Exogenous 
addition of 20-HETE constricted pressurized cat pial arteries in a concentration-dependent 
manner [150].   More recently, 20-HETE was also reported to have an important role in 
constricting small cerebral arterioles and capillaries [148]. 
Cerebral microvessels play a critical role in regulating cerebral blood flow (CBF) by 
significant contributing to the cerebral vascular resistance [148, 232].   By constricting cerebral 
microvessels, pathological 20-HETE production very likely contributes to cerebral 
hypoperfusion and leads to the secondary ischemia observed in multiple neurovascular diseases 
 75 
animal models [8, 203].  We have previously shown that inhibition of 20-HETE formation by 
HET0016 improved cortical perfusion, brain edema, neuronal survival and neurological outcome 
in a pediatric asphyixal CA model in developing rats [27].   In this established CA model, the 
cortical hypoperfusion and hypoxia are well documented [8, 77, 230].   Moreover, a recent study 
by our group reported the heterogenous flow disturbances post-CA in the cortical 
microcirculation in the same model [269].   Using in vivo multiphoton microscopy, we observed 
post-CA arterial vasoconstriction and intravascular stasis, also known as the no-reflow 
phenomenon.   
4.1.3 Hypothesis and Objectives 
To investigate the effect of inhibition of 20-HETE formation on the cerebral microcirculation 
post-CA, we assessed the effect of HET0016 administration at resuscitation using in vivo 
multiphoton microscopy in a clinically relevant pediatric CA model.   We hypothesize that 
intravenous HET0016 administration post-CA alleviates microvascular constriction, therefore 
reduce CBF disturbances post-CA.  In HET0016 treated rats we observed penetrating arteriolar 
dilation.  Prolonged plasma MTT was attenuated after HET0016 treatment.  No significant effect 
of HET0016 was observed on the no-reflow phenomenon compared with vehicle.   Our findings 
suggest that 20-HETE inhibition by HET0016 has a vasodilator effect on cerebral arterioles but 
has no effect on reducing the no-reflow phenomenon.   Combination treatments with multiple 




This study was performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (8th Ed), published by National Research Council and approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.   Male Sprague-Dawley, post-
natal day (PND) 16-18 rats (30-45 g) were used in this study (HET0016 vs vehicle, n=5-
6/group). 
4.2.2 N-hydroxy-N'-(4-n-butyl-2-methylphenyl) Formamidine (HET0016) 
Formulation and Dosage 
N-hydroxy-N'-(4-n-butyl-2-methylphenyl) Formamidine (HET0016) was purchased from 
Maybridge, Cambridge, UK.   A water-soluble formulation of HET0016 was prepared for 
intravenous administration as previously described [270].   Briefly, HET0016 was added into 
15% of (2-Hydroxypropyl)-β-cyclodextrin (HPβCD) (Sigma-Aldrich, Inc.   US) with a final 
concentration of 0.15 mg/mL and agitated for 48 hours at room temperature on a Titer Plate 
Shaker (Lab-Line Instruments, Inc.   US).   The HET0016 solution was then lyophilized to 
complete dryness with a FreeZone 6 Lyopholizer (Labconco, Inc.).   The lyophilized powder was 
reconstituted with phosphate-buffered saline (MP Biomedicals, LLC.   US) before 
administration.   Rats randomized to HET0016 treatment were dosed with 1 mg/kg HET0016 at 
1 min after resuscitation from CA.   Rats randomized to vehicle treatment received the same 
volume of 15% of HPβCD.  Treatment was randomized using random number generator before 
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the experiment started.  The surgical personnel were blinded to treatment until all data was 
collected. 
4.2.3 Surgical Preparation and Asphyxial CA 
An established pediatric asphyxial CA rat model [230] was used with slight modifications for in 
vivo microscopy [269].  Rats were initially anesthetized with isoflurane, orally intubated and 
mechanical ventilated.   After the placement of femoral arterial and venous catheters, we 
discontinued the isoflurane and administered fentanyl intravenously at a constant rate of 50 
μg/kg/h to avoid the vasodilator effect of isoflurane on blood flow.   Vecuronium as 
neuromuscular blockade was infused intravenously at a rate of 5 mg/kg/h.   A heating pad was 
used to maintain the body temperature at 37℃.   An imaging window was created on the skull 
over the parietal area as previously described [269].   The experiment settings are illustrated in 
Figure 4.1A.   Rats were subjected to 12 min asphyxial CA, which produces cortical 
hypoperfusion as previously described using ASL-MRI [8].   The induction of asphyxia and 
resuscitation were conducted as described previously, by stopping mechanical ventilation after 
neuromuscular blockade [269].   Rats were resuscitated in a clinically relevant fashion with, 
bicarbonate (1 mEq/kg iv), epinephrine (0.005 mg/kg iv) and chest compressions until return of 
systemic circulation (ROSC).  HET0016 of 1 mg/kg or the same volume of vehicle were injected 
iv at 1 min after return of systemic circulation (ROSC).   Physiological parameters were recorded 
throughout the experiment, including mean arterial pressure (MAP), end-tidal (Et) CO2 and 
temperature.    
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4.2.4 Cerebrovascular Imaging Using Multi-Photon Microscopy  
The multiphoton microscopy was performed as previously described [269].  Briefly, a Nikon 
A1R MP microscope together with the Nikon Ni-E (Nikon Instruments; Tokyo, Japan) upright 
motorized system were used in the current study.   The microscope was equipped with a 
Chameleon Laser Vision (Coherent, Inc; CA, USA), an APO LWD 25× water immersion 
objective with 1.1 NA, a high-speed (30 frames/second) resonant scanning mode.   We used the 
fluorescence detector 2 for FITC 525 / 50 nm (green channel), an excitation wavelength of 850 
nm and a laser power of 1-2% during the experiment.   All microscope components including the 
laser, stage, resonant scanning head, detectors and acquisition were controlled through the NIS 
Elements software (Nikon).   Post-acquisition image processing was achieved using NIS 
Elements and MATLAB (R2015a, The MathWorks, Inc.   US).   The intravenous dye 
Fluorescein isothiocyanate–dextran (FITC; Sigma, wt 2,000,000) 3% (w/v) 0.1mL was 
administered at baseline to delineate the vasculature (Figure 4.1B).   Additional doses of FITC 
were given as needed to maintain adequate contrast. 
 
4.2.5 Assessment of Cerebral Microvascular Diameter  
To measure the microvascular diameters, image stacks at a resolution of 1µm/ pixel using 
resonant mode were acquired at baseline, and at 5, 30 and 60 min post-CA in 5-6 rats.   The 
cortical microvessels were characterized as previously described [269] into five types: pial 
arterioles, penetrating arterioles, capillaries, penetrating venules, and pial venules, as shown in 
Figure 4.1B.   Micro vascular diameters for the vehicle group were collected from 5 rats and 21 
 79 
pial arterioles, 180 pial venules, 12 penetrating arterioles, 104 penetrating venules, and 440 
capillaries.   The diameters of microvessels in HET0016 group were acquired from 6 rats and 25 
pial arterioles, 163 pial venules, 16 penetrating arterioles, 88 penetrating venules, and 383 
capillaries.   For each animal, 2-5 locations with adequate contrast resolution were identified 
within the imaging window at baseline.   The z-depth of the image stacks reached to a depth 
ranging from 250-400 µm from the pia.   The post-CA stacks (5, 30 and 60 min post-CA) were 
overlaid with the baseline stacks in the x-y-z dimensions in each location.   The vessel diameters 
at each time point were then quantified from a single location per segment from the maximum 
projection of the aligned image stacks using the Annotation and Measurement function in NIS 
Element.   Only the vessels with data acquired at all four-time points were included.    
 
          
  
Figure 4.1 Surgical setting (A) and a representative image of the microvasculature (B) 
A.  The surgical and imaging settings of our experiments.   B.   A representative 3D image of the cortical 
microvasculature, delineated with green pseudo color.   The z depth is about 300 µm.  Different types of micro 
vessels and their relative locations are identified. 
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4.2.6 Assessment of Capillary Red Blood Cell (RBC) Flow (No-reflow 
Phenomenon)  
The assessment of the capillary RBC flow was conducted as previously described [269].   The 
time-series at baseline and post-CA were acquired at the speed of 30 frames/s with resonant 
mode to assess the presence of RBC flow vs.  stasis in the capillaries, which were defined as 
small vessels in parenchyma with diameters of less than 10 µm.   RBCs appeared as oval 
negative signals and a size of 3-6 µm in the bright plasma delineated with FITC (Video 1 A&B).  
The capillary branches were randomly selected at baseline and were followed to 60 min post-
CA.  Time-series of the same capillaries were repeatedly assessed post-CA at 30 and 60 min.   
Absent RBC flow was defined as no RBC flow during the time series (15-30 s).   In vehicle 
group, 82 capillaries from 6 rats were evaluated while in HET0016 group 65 capillaries from 6 
rats were assessed.    
4.2.7 Assessment of Mean Transit Time (MTT) of Plasma  
MTT was assessed at baseline and at 30 and 60 min after CA in HET0016 or vehicle group 
(n=6/group) using a previously described method [239, 269].   Briefly, two regions of interests 
(ROIs), one on a pial arteriole and the other on an adjacent pial venule were identified.   Time-
series were recorded at a speed of 30 frames/s with resonant mode during a bolus of FITC 
dextran (3% w/v, 0.03mL) iv injection at baseline, 30 and 60 min post-CA.   The standard γ 
function was fit to the intensity-time curves in MATLAB.   Time-to-peak (TTP) was defined as 
the time required for the intensity change from baseline to the peak in the fit curves for the artery 
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and vein.   MTT was defined as the difference of TTP between the pial artery and the pial venule 
ROIs at each time point.    
4.2.8 Statistical Analysis 
Means and standard error of the means (SEM) were presented for the continuous variables.   
Data were analyzed by using SPSS (IBM Corp.   IBM SPSS Statistics for Windows, Version 
24.0.   Armonk, NY: IBM Corp.) and figures were generated using Graphpad Prism 6 (GraphPad 
Software, Inc.   La Jolla, CA, USA).   Physiological parameters were tested for time effect within 
each experiment using repeated measurement ANOVA followed by Dunnett’ post-hoc 
comparison.   Microvessel diameters were log transformed and analyzed using a mixed linear 
model with vessels from the same subject nested within each animal.   Dunnett’ post-hoc 
comparisons were conducted within each fixed effect.   In the quantification of capillary RBC 
flow, the number of capillaries with RBC stasis were recorded and fit in a logistic mixed effect 
model with treatment effect as well as time effect using SPSS.   MTT measurements were 
analyzed using two-way ANOVA with Dunnett’ post-hoc comparison.   For all tests, p <0.05 
was considered statistically significant.   The researchers performing the surgical preparation and 
data analysis were blinded to the treatment groups.  The blinding code was broken after data 




4.3.1 Physiological Parameters Summary 
All animals included in the study were successfully resuscitated from CA and had ROSC for at 
least 90 min post-CA.   The physiological parameters recorded for both groups are summarized 
in Table 4.1.   At baseline all physiologic parameters were within normal limits.  Rats had a 
modest temperature reduction post-CA compared to baseline, similar in the vehicle and 
HET0016 group.  No differences were observed in ETCO2 or MAP for each group vs.  baseline 
and between groups.   
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Table 4.1 Temperature, EtCO2, and Mean arterial pressure (MAP) at baseline and post-CA. 
 
 Temperature (℃) EtCO2 (mmHg) Mean Arterial Pressure (mmHg) 
Group baseline 5min post 30min post 60min post baseline 5min post 30min post 60min post baseline 5min post 30min post 60min post 
Vehicle 37.2±0.5 35.3±0.8* 36.1±0.4* 36.6±0.5* 38.0±6.2 40.8±17.2 36.4±15.0 41.8±16.4 58.3±4.1 65.5±13.8 51.7±16.9 55.8±8.0 
HET0016 37.2±0.3 34.3±1.3* 36.3±1.1* 36.6±0.5* 35.8±6.5 29.7±3.4 35.0±8.7 31.3±4.9 62.5±7.6 69.2±16.9 51.3±10.8 49.2±12.0 
*p<0.05 compared to baseline 
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4.3.2 Assessment of Cerebral Microvessel Diameter 
 
Figure 4.2 Representative images of a pial arteriole, pial venule, penetrating arteriole, penetrating 
venule, and cortical capillary at baseline and post-CA from a rat treated with HET0016.    
Pial and penetrating arteriolar dilation at 5 min post-CA is indicated by white triangles.   The penetrating venule 
dilations are also visualized at 60 min post-CA and indicated by white triangles. 
 
The diameter of pial arterioles in rats treated with vehicle was similar to baseline after 12 min of 
asphyxia (31.0±2.6, 33.0±2.4 and 32.0±2.6 vs.  29.8±2.3 µm, 5, 30 and 60 min post-CA vs.  
baseline, p= 0.96, 0.25 and 0.67, at 5, 30, and 60 min vs.  baseline, respectively) (Figure 4.3 A).   
The diameter of pial arterioles in rats treated with HET0016 were also similar to baseline 
(42.1±8.4, 40.7± 8.1, 40.7±8.1 vs 37.1± 7.4µm, 5, 30 and 60 min post-CA vs.  baseline, p= 0.08, 
0.35 and 0.70, at 5, 30, and 60 min vs.  baseline, respectively) (Figure 4.3 A).  Rats treated with 
HET0016 had increased pial arteriolar diameters compared with vehicle-treated rats at 5 min 
post-CA (42.1±8.4 vs 31.0±2.6 µm, p<0.05, HET0016 vs vehicle) (Figure 4.2, 4.3A).   
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The diameters of penetrating arterioles in rats treated with vehicle were similar post-CA 
compared with baseline (27.9±3.5, 28.2±4.0, and 32.1±4.0 vs 28.9± 3.4 µm, 5, 30 and 60 min 
post-CA vs.  baseline, p=0.96, 0.92 and 0.61, at 5, 30, and 60 min vs.  baseline, respectively) 
(Figure 4.3 B).  Penetrating arterioles post-CA in rats treated with HET0016 had increased 
diameter compared with baseline (34.3±2.3, 32.8±2.6 and 37.3±3.0 vs 28.7±2.1 µm, 5, 30 and 60 
min post-CA vs.  baseline, respectively, p<0.05 at 5, 30, and 60 min vs.  baseline) (Figure 4.2, 
4.3B).   HET0016 treatment showed a trend towards increased penetrating arteriolar diameter at 
5 min post-CA compared with vehicle group (34.3±2.3 vs 27.9±3.5µm, p=0.051) (Figure 4.3 B).  
There was no difference between treatment groups in the diameters of penetrating arterioles at 30 
and 60 min post-CA (p=0.175,0.197, respectively).    
Capillaries in rats treated with vehicle had increased diameter at 5 and 60 min post-CA 
compared with baseline (5.9±0.1, 6.1±0.1 vs.  5.5±0.1µm, 5, 60 min post-CA vs baseline, 
p<0.05) (Figure 4.3 C).  The diameters of capillaries in rats treated with HET0016 remained 
similar with baseline (6.0±0.1, 5.9±0.1, and 6.3±0.2 vs 5.9±0.2 µm, 5, 30 and 60 min post-CA 
vs.  baseline, p=0.82, 0.97 and 0.13, respectively) (Figure 4.2, 4.3 C).   There was no difference 
between treatment groups in the diameters of capillaries post-CA.   
Penetrating venules in rats treated with vehicle had increased diameter at only 60 min 
post-CA compared with baseline (21.8±2.1 vs 19.2±1.9µm, 60min post-CA vs baseline, p<0.05).   
The diameter of penetrating venules in rats treated with HET0016 increased at 5 and 60 min 
post-CA compared to baseline (22.8±1.2, 23.9±1.1 vs 21.1±1.2µm, 5, 60min post-CA vs 
baseline, p<0.05) (Figure 4.2, 4.3 D).  The diameters of penetrating venules in rats treated with 
HET0016 were similar to the ones treated with vehicle post-CA. 
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Pial venules in rats treated with vehicle had increased diameter at 60 min post-CA 
compared with baseline (19.5 ± 0.7 vs 17.7±0.7µm, 60 min post-CA vs baseline, p<0.05) (Figure 
4.2, 4.3 E).    Pial venules in rats treated with HET0016 remained similar to baseline (19.8±0.9, 
19.1±0.9, and 19.2±0.9 vs 18.8±0.9 µm, 5, 30 and 60min post-CA vs baseline, p=0.09, 0.89, and 
0.92, respectively).   There was no difference between treatment groups in the diameters of pial 
venules post-CA.   
 
 
Figure 4.3 Microvascular diameter changes post-CA. 
Diameter changes for pial arterioles (A), penetrating arterioles (B), capillaries (C), penetrating venules (D) and pial 
venules (E).   Data were collected from 6 post-natal day 16-18 rats at baseline and post CA from each group.   In the 
HET0016 group, the diameters of pial arterioles increased at 5 min post CA vs.  vehicle (* p<0.05).   The 
penetrating arterioles dilated post-CA vs.  baseline (# p<0.05).  In the vehicle group, the diameters of capillaries 
increased at 5 and 60 min post CA compared with bassline (# p<0.05).   The penetrating venules dilated at 5 and 60 
min in the HET0016 group post-CA vs.  baseline (# p<0.05).  In the vehicle group the diameters of the pial and 
penetrating venules increased at 60 minutes post-CA vs.  baseline (# p<0.05) 
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4.3.3 Assessment of Capillary RBC Flow (No-reflow Phenomenon) 
We assessed the continuity of RBC flow in the cortical capillaries at baseline and post-CA in 
both vehicle and HET0016 groups.   At baseline, all capillary branches had continuous RBC 
flow (Supplementary video V1).   After CA, stagnant RBCs were seen in capillaries in all rats 
(Figure 4.4, Supplementary video V2).  Absence of RBC flow was observed most often in one of 
the capillary branches of a capillary network, while in the other branches RBC flow remained 
continuous (Supplementary video V3).   In some capillaries, the stasis of RBCs resolved at later 
time points (Supplementary video V4), while in other capillaries the RBC stasis persisted to the 
end of the observation period (Figure 4.4).   
Stagnant RBCs were present in all the rats at least at one time point in both vehicle and 
HET0016 group.   Overall, in the vehicle group, 26.4% of capillary branches had no-reflow at 30 
min post-CA.  This phenomenon gradually recovered and11.7% capillaries with no-reflow were 
present at 60 post-CA (Figure 4.4).   Similar trends were observed with HET0016 treatment with 
absence of RBC flow observed in 28.9% and 12.3% capillary branches at 30 and 60 min post-
CA, respectively (Figure 4.4).   There was no difference between treatment groups in the 
proportion of capillaries with no-reflow post-CA.     
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Figure 4.4 Capillary RBC flow after CA. 
Representation of percent of capillaries in each rat with absence of RBC flow post-CA for the HET0016 and vehicle 
groups.  Each dot of the scatterplot represents an independent animal. 
4.3.4 Assessment of Mean Transit Time (MTT) of Plasma  
Figure 4.5 illustrates MTT of representative rats from the vehicle group (5A) and from HET0016 
group (5B).  MTT in the vehicle group was similar at 30 min post-CA compared with baseline 
(2.0 ± 0.3s vs 1.6 ±0.3s, p=0.35) but increased 60 min post-CA compared with baseline 
(2.7±0.7s vs 1.6 ±0.3s, p<0.05) (Figure 4.5C).  MTT post-CA in HET0016 group was similar to 
baseline (1.9 ± 0.2s and 1.8 ±0.2s vs 1.3 ±0.1s, 30min and 60 min post-CA vs baseline, p= 0.09 
and 0.16, respectively).  No difference was observed in MTT between two treatment groups.    
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Figure 4.5 Mean transit time of plasma through the cortical microcirculation.    
Representative intensity-time curves and γ fit curves at baseline, 30, 60 min post-CA (left to right) from HET0016 
(A) and vehicle group (B).   MTT increased post-CA, indicated by the black arrows.   C.   MTT increased post-CA 
at 60 min vs.  baseline in the vehicle group (# p<0.05) (n= 6/group). 
4.4 DISCUSSION 
To our knowledge this is the first study assessing the direct vasodilatory effect of 20-HETE 
inhibition after CA.  We have recently shown in our pediatric asphyxial CA model that 20-HETE 
levels are increased in the cortex at 5 min after resuscitation, and 20-HETE inhibition with 
HET0016 reduced the 20-HETE level in cortical homogenates [27].  Treatment with HET0016 
improved cortical perfusion as assessed by Laser Speckle and improved neurological outcome 
and neurodegeneration in this model [27].  As 20-HETE has dual neuronal and vascular effects 
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[148, 155, 266, 268], our previous in-vivo studies did not allow to directly assess the direct 
vascular contribution of 20-HETE inhibition.  In our current work we directly assessed the 
cortical microcirculation in vivo using multi-photon microscopy.  Inhibition of 20-HETE 
formation had a trend towards early and transient pial arteriolar dilation, produced sustained 
dilation of the penetrating arterioles, reduced the transit time of plasma in the cortex, and had no 
effect on the capillary no-reflow.  Our results suggest that inhibition of 20-HETE formation by 
HET0016 exerts its main vascular effects on the penetrating arterioles.   
HET0016 treatment produced dilation of penetrating arterioles compared with baseline.  
Compared with vehicle, HET0016 transiently dilated pial arterioles immediately after ROSC, 
and had a trend towards dilation of penetrating arterioles.  Cerebral microvascular flow is 
arranged such that an abundant lattice of surface pial microvessels gives raise to much fewer 
penetrating arterioles.  Distinct cortical territories are supplied by a single penetrating arteriole, 
and thus penetrating arterioles can considerably limit the blood flow influx to large cortical area 
that extend up to 350 µm in radius [271].  Pial and penetrating arterioles contribute to a 
significant portion of the resistance, as regulation of the cortical microcirculation system is 
dependent on the regulation of arteriolar flow [272, 273].   The vasodilator effect observed at the 
level of penetrating arterioles is physiologically important as cortical perfusion is inversely 
related to the cerebral vascular resistance by the 4th power of vessel diameter [272, 274].   
According to Poiseuille's equation, an arterial constriction of 10% is expected to produce a CBF 
reduction of ~36%.  In the current study, we observed ~20% arteriolar dilation at 5 min post-CA 
which could lead to dramatic change in flow as well as the perfusion pressure downstream. 
We also observed the unchanged plasma MTT after HET0016 treatment in contrast to 
increased MTT post-CA in rats treated with vehicle.  The improvement of cortical transit time of 
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plasma could be a downstream effect of arteriolar dilation and reduced flow resistance.  MTT is 
directly proportional to cerebral blood volume (CBV) and inversely related to CBF.  Since 
cerebral capillaries and venules serve as a reservoir for CBV, capillary and venular dilation in 
both HET0016 and vehicle groups indicates increased CBV for both groups.  In the context of 
increased CBV, unchanged MTT suggests increased CBF, consistent with the effect of arteriolar 
dilation in the absence of an effect of HET016 on capillary flow. 
Capillary no-reflow was not affected by the HET0016 treatment.  As a downstream effect 
of arteriolar dilation post-CA in HET0016 treated rats, the perfusion pressure gradient may 
decrease, and therefore, RBCs stasis in the capillary bed may not be affected.  Worth noting is 
that this is the first report of in vivo no-reflow phenomenon in a prolonged duration of CA.  We 
have recently reported capillary no-reflow in a less severe albeit significant CA of 9 min and 
observed no-reflow in 60% of rats studied.  Importantly, after 12 min CA no-reflow is observed 
in all rats.  The observation of increased no-reflow with increased insult duration is similar to the 
original ex vivo description of the no-reflow  phenomenon by Ames [171]. 
 The vehicle used in the study is HPβCD, necessary to reconstitute HET0016.  It is 
possible that the compound HPβCD has vasodilator properties via stimulation of NO release, 
which could reduce the net effect of HET0016 vasodilation observed here.  A recent study 
reported that HPβCD induced angiogenesis in cultured endothelial cells, effect mediated by the 
endothelial nitric oxide synthase (eNOS)/NO pathway [275].  Furthermore, one important 
mechanism proposed of NO vasodilation is via inhibition of 20-HETE synthesis [148], which 
could also explain the absence of arteriolar constriction post-CA in the vehicle group and the 
apparent lack of observed difference between vehicle and HET0016 groups.   
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Our study underlines two important factors in optimizing perfusion to decrease secondary 
insults after cerebral ischemic events.  First, in evaluating CBF-directed therapies, direct in vivo 
observation of microcirculatory flow is important to optimize perfusion.  In this model, a 
vasodilator therapy produced arteriolar vasodilation, however did not affect the nutrient blood 
flow at the capillary level.  Consequently, therapies that affect vasomotor tone ought the be 
combined with therapies promoting capillary flow for maximal cerebral perfusion benefit to 
decrease secondary insults.  Combinations of vascualar-targeted therapies have been proposed 
and some achieved long-term outcome improvement after CA.  Studies by Safar, et al.  applied 
flow promotion (norepinephrine), hypervolemic hemodilution and heparinization at resuscitation 
of CA.  Mitigation of both no-reflow and delayed hypoperfusion were achieved post-CA [203, 
276].   Nitroglycerin has also been proposed to use in addition to vasopressors to improve 
outcome [277].   Superoxide dismutase and deferoxamine were combined for better recovery of 
cerebral blood flow post-CA [26].   Synergic effect of hypothermia and 20-HETE were also 
evaluated in hypoxia-ischemia piglet model [278].  Utilizing therapies with complementary 
mechanisms, and optimizing the compound structures, dosage and intervals will be necessary to 
identify optimal therapeutic combination aimed at improving outcome after CA.  
We also recognize that we did not assess cerebral metabolic rate (either glucose or 
oxygen utilization) after resuscitation in our model and specifically the impact of HET0016 on 
cerebral metabolism and/or brain tissue partial pressure of oxygen (PbO2).  In prior work, we 
have reported that PbO2 is critically reduced in the cortex for several hours after resuscitation in 
this model,[279] and thus future studies assessing the impact of HET0016 on tissue hypoxia are 
warranted. 
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In conclusion, 20-HETE formation inhibition by HET0016 has arteriolar vasodilator 
effect in vivo, attenuates increased cortical transit time of plasma post-CA, and does not affect 
RBC stasis post-CA in a 12 min asphyxial CA model in developing rats.  Therapies targeting the 
capillary no-reflow are needed in addition to arteriolar dilators to improve blood flow post-CA.   
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5.0  PRELIMINARY CLINICAL STUDY OF 20-HETE AND CO2 REACTIVITY AS TWO 
BIOMARKERS IN ANEURYSMAL SUBARACHNOID HEMORRHAGE PATIENTS 
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5.1 INTRODUCTION 
Subarachnoid Hemorrhage (SAH) is a devastating neurovascular disease which accounts for 5% 
of stroke with high fatality [280].  Delayed cerebral ischemia (DCI) is a major contributing factor 
of poor neurological outcome and morbidity [280].  Despite similar severities on presentation, 
patients develop a widely disparate range of outcomes in days after aneurysm repair.  Current 
hypertensive therapy treatment is uniformly applied to patients to prevent vasospasm regardless 
of the assessment of their vascular reactivity. The validity of hypertensive therapy assumes that 
constricted vessels due to vasospasm can be re-opened under hypertension. However, if cerebral 
vessels in certain patients are not responsive to any stimuli, these patients would not benefit from 
hypertensive therapy. Instead, they could be subjected to unnecessary complications such as 
secondary hemorrhage or brain edema, which could further worsen the outcome.  Previous 
clinical study suggests 20-hydroxyeicosatetraenoic acid (20-HETE), a potent vasoconstrictor for 
small vessels as a biomarker for aSAH patients [281].  In this chapter, we will further discuss the 
role of 20-HETE in aSAH patients as a biomarker and establish the association of 20-HETE and 
vascular reactivity in aSAH patients. 
5.1.1 Epidemiology of SAH 
SAH is a form of hemorrhagic stroke which affects 30,000 patients in the United States annually 
[282].  Aneurysmal SAH (aSAH) is the major type in 85% SAH patients and occurs at a fairly 
young age.   Half of the patients are aged less than 55 at the time of the hemorrhage [283].  
Given the advances in early repair of ruptured aneurysms and postoperative management, SAH 
remains to be a devastating disease due to high mortality rate (~50%) and low functional 
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independence in survivors (<60%) [282].  Current treatments include endovascular obliteration 
by platinum spirals and neurosurgical clipping, as well as prophylactic administration of 
nimodipine.  Hypertension and hypervolemia are induced to prevent cerebral vasospasm 
uniformly in aSAH patients, while the efficacy is questioned by multiple complications such as 
cerebral hemorrhage, and cerebral edema [284].  Patients who survive the initial hemorrhage 
often suffer from permanent neurological, cognitive, or functional deficits.  It is estimated that 
the cost to the society of SAH is greater than that of ischemic stroke [285].   
5.1.2 Neurological Deterioration and Delayed Cerebral Ischemia (DCI)  
More than 40% of SAH patients develop neurological deterioration in 3-14 days after aneurysm 
repair regardless of injury severity [280].  Neurological worsening which cannot be attributed to 
intracranial or systemic complications is attributed to DCI [280, 286].  DCI is attributed to poor 
outcome or even death in 30% SAH patients [286, 287], however, the diagnosis of DCI is poorly 
defined or even missing in clinical studies [280, 288].   
The mechanism of neurological deterioration remains unclear but multiple factors are 
thought to be involved in the pathogenesis, including angiographic vasospasm, cortical spreading 
ischemia, micro thrombosis and microcirculation constriction [286].  Angiographic vasospasm, 
for example, is found in two-thirds of aSAH but only half of these patients developed DCI [289, 
290].  Therapies targeted at large vessels such as endothelin receptor antagonists have shown 
benefits in vasospasm but not in DCI [291, 292].  Recent evidence suggests microvascular 
dysfunction and complex neuronal-glial interactions play an important role in the development of 
DCI and neurological deterioration [227, 291].   
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5.1.3 Cerebrovascular Reactivity in aSAH Patients 
Cerebrovascular reactivity describes the change of CBF in response to a certain vasoactive 
stimulus.  The utilization of CO2 inhalation to map cerebrovascular reactivity has gained 
application in recent literature due to its potency in vasodilation, good safety profile and fast 
onset as well as cessation [293].  Intact cerebrovascular reactivity enables normal autoregulation 
therefore serves as the premise for multiple vasodilatory therapies.  Impaired CO2 reactivity has 
been documented in the literature for animal studies as well as aSAH patients [294-297].  
However the utilization of CO2 reactivity to predict patient outcome has not been fully validated.  
Hassler et al.  demonstrated a weak hypercapnic response in vasospastic aSAH patients [298]. A 
study by Fierstra and colleagues reported lower reactivity in the early phase of 18 aSAH patients 
but did not predict vasospasm or functional outcome [297].  Currently, CO2 reactivity is not 
routinely monitored as standard of care for aSAH patients.  However, profiles of cerebrovascular 
reactivity could provide useful insights to identify vulnerable or responsive subpopulations and 
to tailor vasoactive therapies for aSAH patients.    
5.1.4 20-HETE as a Biomarker in aSAH 
20-HETE is a potent microvascular vasoconstrictor in renal, mesenteric, and cerebral vascular 
beds and plays an important role in determining cerebral vascular tone and autoregulation [299].  
Previous pre-clinical and clinical studies have demonstrated that 20-HETE may contribute to 
DCI in aSAH [281, 300-302].  Donnelly et al.  reported moderate to high level of CSF 20-HETE 
was associated with 3-fold higher mortality and worse outcome in aSAH patients [281].  Similar 
association was replicated by another group [300].  However, the utilization of CSF samples 
 98 
limited the access to aSAH patients without CSF drainage and the generalizability of the 
conclusion in other neurovascular diseases.  Therefore, the correlation of plasma and CSF 20-
HETE concentrations is needed to increase the generalizability of current data. 
5.1.5 Hypothesis and Objectives 
 
Figure 5.1 Schematic presentation of the hypothesis 
The current gap in knowledge is to determine the role of 20-HETE in cerebral vascular 
reactivity and to determine if these indices can be used as a basis for individualized care to 
improve poor outcomes in aSAH patients.  We hypothesize that plasma 20-HETE concentration 
is correlated with CSF therefore could potentially serve as a prognosis biomarker for aSAH 
patients. We also hypothesize that CO2 reactivity serves as a prognosis biomarker for aSAH 
patients which could predict mortality, and short- and long-term outcome (Figure 5.1).  To test 
these hypothesizes, first we need to establish the association between plasma and CSF 20-HETE 
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concentration in aSAH patients.  Second, we need to assess CO2 reactivity in SAH patients and 
establish the correlation between CSF 20-HETE level and CO2 reactivity.   
5.2 METHOD  
5.2.1 Study Design and Sample Collection 
5.2.1.1 Study to Assess Plasma and CSF 20-HETE Correlation  
Plasma and CSF samples were previously obtained from aSAH patients who were recruited in 
the University of Pittsburgh Medical Center (UPMC) neurovascular intensive care unit between 
October 2000 and August 2010 [303].  The Institutional Review Board of the University of 
Pittsburgh approved the protocol and informed consent was obtained from the patient or their 
proxy prior to sample collection (IRB Protocol number: PRO 021039).  Patients included in this 
study were adults aged 18–75 years, diagnosed with aSAH via cerebral angiogram or head 
computed tomography (CT).  Criteria for enrollment also included Fisher grade >1 and CSF 
access (ventriculostomy or lumbar drain).  The exclusion criteria are a history of debilitating 
neurological disease or SAH from trauma, mycotic aneurysm or arteriovenous malformation. 
CSF and plasma were withdrawn by registered nurses directly from the CSF tubing and 
venous catheter each morning (8am+/−1 hour) and evening (7pm+/−1 hour) through 14 days 
after initial hemorrhage (contingent on CSF access).  All specimens were frozen and stored at 
−80 degrees for batch analysis.   
To establish the correlation of 20-HETE levels in the plasma and CSF, 35 aSAH patients 
were selected based on their CSF levels previously measured by Mark Donnelly [281] and 
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categorized into three groups: high (maximum CSF 20-HETE>1ng/mL, 11 subjects), medium 
(maximum CSF 20-HETE between 0.1-1 ng/mL, 12 subjects) and low (maximum CSF 20-HETE 
<0.1 ng/mL, 12 subjects). 
5.2.1.2 A Pilot Feasibility Study to Assess CO2 Reactivity Following SAH 
This is a prospective, interventional clinical study in adult aSAH patients (IRB Protocol number: 
PRO16030073) at UPMC neurovascular intensive care unit.  The Institutional Review Board of 
the University of Pittsburgh approved the protocol (Appendix III).  The study design is depicted 
in Figure 5.2. 
 
Figure 5.2 Study design for CO2 reactivity in aSAH patients 
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Medical stability assessment is based on vital signs (heart rate, blood pressure, ICP, CPP, 
respiratory rate, SpO2).  If the patient had high intracranial pressures (ICP > 30) or respiratory 
distress - SaO2 < 92%, RR > 30, no challenge study would be attempted.  Pre-challenge 
recordings included stable mean blood flow velocity (mBFV) of bilateral middle cerebral artery 
(MCA) and internal carotid artery (ICA) measured by transcranial Doppler (TCD) (Natus 
Neurology, Middleton, WI) and end-tidal CO2 (EtCO2).  EtCO2 level was continuously 
monitored by a capnograph connected to a face mask in non-intubated patients or the ventilator 
circuit in intubated patients.  The CO2 challenge was done by inhalation of 5% CO2 (Matheson 
Tri-Gas, Inc.  Montgomeryville, PA) until a 6 mm Hg absolute increase in EtCO2 level was 
achieved.  After this level was reached, the tubing was disconnected in in non-intubated patients 
or ventilator settings were reset to pre-testing values in intubated patients.  CO2 levels and TCD 
values continued to be measured until they reach pre-challenge levels. 
Inclusion criteria: 1) Newly (within 5 days) SAH diagnosis verified via CT and cerebral 
angiogram and Fisher grade >2: Degree of hemorrhage that increases complication risk; 2) Over 
21 years; able to read/ speak English; and 3) No history of previous neurological disorders; 4) 
Patients who have consented IRB 021039 for plasma and CSF collection. 
Exclusion criteria: 1) Women who were pregnant; 2) Patients with unstable respiratory 
failure as indicated by FiO2 need > 80%, SaO2 < 92%; PEEP > 10.  3) Patients with unstable ICP 
as indicated by ICP > 30. 
Prior to the CO2 challenge in aSAH patients, 8 healthy volunteers (4 men and 4 women) 
participated and validate the CO2 challenge under current settings.  Oral consent was obtained 
from these volunteers.  Five aSAH patients were recruited into current study and only 4 patients 
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had CSF collection.  CO2 reactivity was calculated as percentage change of MCA velocity 
divided by absolute change in EtCO2 [304].   
5.2.2 Outcome Assessment 
Hunt & Hess grade (HH), vasospasm and modified Rankin Scale score (mRS) at discharge and 3 
months later were assessed in all 5 patients recruited as previously described [281].  Briefly, HH 
and mRS were assessed at discharge by experienced medical personnel.  Cerebral vasospasm 
was evaluated by angiography and graded from 0 to 5 based on severity by neurology surgeons.  
The mRS score was also obtained after 3 months of discharge during a face-to-face interview or 
phone call with the patient or their surrogate. 
5.2.3 Sample Analysis  
CSF and plasma concentrations of 20-HETE were determined using a modified and validated 
assay previously described [305].  Both samples were processed using solid phase extraction.  
Briefly, CSF sample volumes of 2.0-3.0 mL (or plasma sample volumes of 0.5 mL) were loaded 
onto 3cc (or 1cc) Oasis HLB-SPE cartridges (Waters, Milford, MA, USA).  Columns were 
washed and eluted with 3 mL (or 1 mL) of 5% methanol and 100% methanol, respectively.  
Samples were reconstituted in 50 μL or 125 μL of 80:20 methanol:water.  Quantification of 20-
HETE was performed by UPLC-MS/MS with minor modifications [305].  Concentrations of 20-
HETE were determined from the standard curve of peak area ratio utilizing 20-HETE-d6 as an 
internal standard.  For measurements below the limit of quantification, value of half limit of 
quantification was assigned.   
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5.2.4 Data Analysis and Statistics 
Descriptive statistics were used to summarize the measurements.   Means and standard deviation 
were presented for the continuous variables.  Correlation analysis was performed to evaluate the 
correlation of 20-HETE levels in CSF and plasma samples from aSAH patients in GraphPad 
Prism 7 (GraphPad Software, Inc.   La Jolla, CA, USA).  Pearson correlation coefficient was 
calculated to estimate the correlation.  Hierarchical cluster analysis was performed to explore the 
subgroups within all the samples collected in SPSS (IBM Corp.  IBM SPSS Statistics for 
Windows, Version 24.0.  Armonk, NY: IBM Corp).  Paired t-test was performed to assess the 
change of EtCO2 and MCA velocity in healthy volunteers at baseline and during CO2 challenge.  
For all the test, p-value<0.05 was considered statistically significant.    
5.3 RESULTS 
5.3.1 Temporal Alteration in CSF and Plasma 20-HETE Levels  
To evaluate if the plasma 20-HETE levels reflect the temporal variation of CSF 20-HETE 
concentration, 20-HETE levels were plotted for individual patient from all groups (Figure 5.3).  
In almost all patients plotted, the pattern of plasma 20-HETE level did not show consistency with 
CSF 20-HETE fluctuations within patients.  In high CSF 20-HETE group, most 20-HETE levels 
are higher than plasma levels.  In low CSF 20-HETE group, 20-HETE levels in the plasma 
overshot the ones in the CSF.  While in the medium CSF group, 20-HETE levels in the plasma 
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are either higher or lower than those in the CSF.  The peak concentrations of 20-HETE 
concentration in the CSF was not followed by plasma levels.   
 
 
Figure 5.3 Temporal variation of CSF and plasma 20-HETE concentrations in individual aSAH patient 
5.3.2 Correlation of 20-HETE Levels in CSF and Plasma 
Since the number of samples pulled from each patient varies, we assessed the maximum 20-
HETE CSF level and the corresponding plasma level as presented in figure 5.4.  There is no 
correlation between plasma and maximum CSF 20-HETE concentrations in aSAH patients.   
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Figure 5.4 Maximum CSF level and corresponding plasma levels from 35 aSAH patients 
A total of 123 plasma samples from 35 patients were pulled from the biobank freezer for 
analysis.  As presented in figure 5.5, there was a trend toward correlation between plasma and 
CSF 20-HETE levels, however, it is not statistically significant.  The correlation coefficient is 
0.176 for all the samples.   
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Figure 5.5 Plasma and CSF 20-HETE levels from 35 aSAH patients.  Each color represents an 
individual patient 
 
A trend of separation was noticed in figure 5.5, therefore cluster analysis was performed 
using Hierarchical cluster analysis and two subgroups were identified as depicted in figure 5.6.  
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Correlation between CSF and plasma 20-HETE concentrations was significant within each 
subgroup.  Correlation coefficient also improved in both subgroups.   
 
Figure 5.6 Samples groups by Hierarchical cluster number 
5.3.3 CO2 Reactivity in aSAH Patients 
Prior to the measurement of CO2 reactivity in aSAH patients, the CO2 challenge was validated in 
8 volunteers under current clinical settings.  Each test was finished within 10 minutes and 
volunteers did not express any discomfort during the test.  As expected, MCA velocity increased 
during the challenge compared to baseline, as EtCO2 increased during the challenge (Data not 
shown).    
A total of 5 aSAH patients were recruited in the study so far (Table 5.1).  Inhalation of 
CO2 resulted in increased EtCO2.  MCA velocity increased in left and right MCA velocity in 
most measurements.  However, heterogeneous MCA velocity change was observed in aSAH 
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patients.  The MCA velocity increased or decreased within the same patient at different days post 
injury.  The left and right MCA velocity was not always associated on the same day for the same 
patients. 
  
Table 5.1 Summary of MCA velocity change and 20-HETE levels in aSAH patients 















1962 3 23 29 24.69 4.12 35 5.83 0.01 
1962 4 20 27 94 13.43 6.33 0.9 0.01 
1962 5 29 35 -9.64 -1.61 38.81 6.47 0.01 
1962 7 34 40 9.91 1.65 17.48 2.91 0.01 
1981 6 24 32 6.52 0.82 3 0.38 0.03 
1982 7 24 31 33.33 4.76 27.78 3.97 NA 
1982 8 23 29 17.24 2.87 56.14 9.36 0.01 
1982 9 23 30 6.9 0.99 10 1.43 0.01 
1983 4 24 33 NA NA 4.76 0.53 0.01 
1985 5 23 29 20.63 3.44 21.88 3.65 0.01 
1985 6 24 32 87.72 10.96 18.42 2.3 0.01 
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Figure 5.7 CO2 reactivity for aSAH patients 
CO2 reactivity was calculated for aSAH patients (Figure 5.7) and aSAH patients 
displayed a wide range of CO2 reactivity.  Within the same patient (1962), CO2 reactivity varied 
at different days post injury.  The left and right CO2 reactivity were not always correlated on the 
same day for the same patient.   
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5.3.4 CSF 20-HETE Levels in aSAH Patients 
As depicted in Table 5.1, CSF was collected and analyzed in 4 aSAH patients.  Most patients had 
very low 20-HETE levels in the CSF.  Patient 1981 had a relative higher level of 20-HETE at the 
time of the CO2 reactivity assessment.   
5.3.5 Patient Outcome Assessment  
Outcome assessment results were summarized in Table 5.2 for all patients recruited.  Only 
patient 1985 had vasospasm during hospitalization and relatively worse outcome compared with 
other patients at discharge and after 3 months.  Patient 1981 also had poor outcome at discharge 
despite of no vasospasm presented.   
Table 5.2 Outcome assessment for aSAH patients 
Patient ID HH score Vasospasm mRS score at discharge 3 months mRS score 
1962 3 0 4 2 
1981 4 0 5 3 
1982 2 0 1 0 
1983 2 0 1 0 
1985 5 3 5 4 
 
5.4 DISCUSSION AND CONCLUSION 
This is a pilot clinical study to explore the potential of utilizing CO2 reactivity and 20-HETE 
levels as two biomarkers in aSAH patients.  In the retrospective study, poor correlation was 
found between plasma and CSF 20-HETE levels either within the same patient or in all aSAH 
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patients.  The correlation improved in subgroups after cluster analysis, suggesting different 
mechanisms of 20-HETE production and accumulation in certain portion of the patients.  In the 
prospective interventional study, we validated the CO2 reactivity measurement under current 
clinical setting in both healthy volunteers and aSAH patients with well-tolerated safety profile.  
aSAH patients displayed a widely disparate range of CO2 reactivity with temporal variations and 
no signs of symmetry.  A larger sample size of aSAH patients is needed to establish the 
association between 20-HETE levels and CO2 reactivity. 
As a potent vasoconstrictor, 20-HETE is produced by cytochrome P450 4A and 4F 
subfamilies localized in vascular smooth muscle cells, endothelial cells, neurons and astrocytes 
in the brain [150, 155, 299, 306].  The expression of CYP 4A has been found higher in small 
arterioles and an inversely proportional correlation was found in 20-HETE production and vessel 
diameter [307, 308].  20-HETE as a fatty acid should be freely diffusible across membranes and 
blood-brain-barrier, and plasma 20-HETE has been associated with neurological deterioration 
acute minor ischemic stroke [309].  In current aSAH population, the correlation of plasma 20-
HETE and CSF 20-HETE levels is weak for all samples but improved in subgroup analysis.  
This might suggest a burst local production of 20-HETE in the brain override the plasma levels 
in some patients at certain time points and contribute to the pathogenesis of worse outcome.  In 
other patients whose plasma 20-HETE levels are comparable or higher than CSF levels, local 
production of 20-HETE is not predominant.  Precautions should be taken when interpreting 
systemic levels for paracrine biomarkers.  An important limitation in current study is the possible 
selection bias when picking samples from high, medium and low CSF 20-HETE groups.  This 
could limit the generalizability of the conclusion to a different population.  To further elucidate 
the pathogenesis of 20-HETE production, pre-clinical models and clinical studies with large 
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sample size should be conducted. It is possible that plasma 20-HETE could still serve as a 
biomarker independently from CSF levels. To further explore the potential of plasma 20-HETE 
as a biomarker for aSAH patients, multiple covariates such as injury severity (Fisher score), 
gender, age, vasospasm, etc. could be incorporated to test whether plasma 20-HETE is a 
significant predictor of patient outcome or mortality. 
The CO2 reactivity in aSAH patients displayed a wide range of variation compared with 
healthy volunteers.  Such temporal and regional heterogeneity delineates the impaired 
cerebrovascular reactivity in current patient population.  Similar findings are observed in the 
literature [296, 297].  Due to limited sample size, no correlation could be attempt between 20-
HETE levels and CO2 reactivity or patient outcome.  The heterogeneous profile observed in 
these 5 patients complicates the categorization of patients since “non-intact” reactivity is 
insufficient to describe patient CO2 reactivity.  The same patient may exert impaired reactivity in 
only a day or two with one hemisphere but normal reactivity in other days.  However, 
hypertensive therapy given when cerebrovascular reactivity is poor could do harm than good to 
the patient. This is because hypertensive therapy assumes that constricted vessels could be 
dilated or re-opened if perfusion pressure is increased. However, in patients with non-intact 
cerebrovascular reactivity, cerebral vessels would not respond to increased pressure. These 
patients would not benefit from hypertensive therapy; instead, they would unnecessarily suffer 
from complication due to hypertensive therapy.  Also it is necessary to establish an algorithm to 
describe the extent of impaired reactivity in aSAH patients and tailor treatment based on the 
extent.  Previous publication used normalized autoregulatory response (NAR) as an index to 
describe patient cerebrovascular reactivity, however, the definition of NAR is variable across 
studies and no threshold was consistently accepted to distinguish impaired NAR versus normal 
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values [296, 310-312].  It is also difficult to use NAR as an appropriate index since duration is 
not included in the calculation.  A more comprehensive measurement should be established to 
better capture the dynamic change of cerebrovascular reactivity.  Continuous or periodic 
monitoring of CO2 reactivity is necessary to characterize the profile with more aSAH patients. 
Once the dynamic profile of CO2 reactivity is characterized, other clinical covariates, such as 
gender, age, injury severity, days post injury, brain edema scores could be incorporated to 
systemically assess whether CO2 reactivity is a significant predictor of aSAH patient outcome 
and/or mortality. 
In conclusion, we conducted a pilot clinical study to explore the potential of 20-HETE 
plasma concentration and CO2 reactivity as two biomarkers for aSAH patients.  Both biomarkers 
are potentially useful in providing insights to understanding the pathogenesis of neurological 
deterioration in aSAH patients.  Further studies with large sample size are required to establish 
the association between each biomarker with patient outcome.   
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The aim of this dissertation is to explore and describe the role of cerebral microvascular 
alterations in both clinically relevant animal model and clinical patients who are subjected to 
neurovascular diseases, including CA and SAH.  Three approaches were adopted to fulfill this 
aim.  In Chapter 2, an extensive systematic review was conducted to summarize the current 
understanding of pharmacological therapies used for CA and global ischemia, with emphasis on 
cerebral microcirculation.  In Chapter 3 and 4, an in-vivo multiphoton microscopy platform was 
established for a pediatric CA model to better evaluate the pathophysiology and pharmacology 
for cerebral microcirculation in CA.  Lastly in Chapter 5, the role of a vessel constrictive fatty 
acid, 20-HETE was explored for its potential as a biomarker in the plasma from aSAH patients, 
together with cerebrovascular reactivity. 
 
6.1.1 Systematic Review on Pharmacological Therapies after CA 
In this review, we summarized the current understanding of pharmacological therapies with their 
effect on CBF after CA and global ischemia.  Five categories of therapies were identified based 
on mechanism of reaction: flow promotion, vessel dilatory, thrombolytic, hemodynamic, and 
antioxidant therapies.  Each category targets on different determinants of CBF.  For example, 
flow promotion therapies mostly increase perfusion pressure at resuscitation therefore improve 
CBF while vessel dilatory therapies are expected to decrease vascular resistance and improve 
CBF. 
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Early studies focused on cerebral macrovasulcar alterations, probably due to limited CBF 
measurement methods.  Recent advances in methodology such as MRI enable more detailed 
temporal, regional and dimensional characterizations of CBF, emphasizing cerebral 
microcirculation as an important target.  At the same time, questions rise to the traditional 
therapies, such as epinephrine and heparin, regarding to their effects on cerebral 
microcirculation.  Epinephrine, for example, has been used as a standard of care for CA 
resuscitation over 40 years.  Recently, detrimental effect of epinephrine was reported to decrease 
microcirculatory perfusion in CA model [46].   Different temporal and dimensional CBF profile 
post-CA in addition to the pharmacology profile of each therapy, suggests that sequential or 
combination therapies might be beneficial. 
After a thorough review of the literature, we identified three knowledge gaps.  First, the 
understanding of temporal and regional alterations of cerebral microcirculation post-CA is 
lacking, especially for different types of small vessels such as small arterioles and capillaries.  
This is very important because the alterations in different types of vessels suggest potential 
therapeutic targets therefore direct to specific treatments.  Second, a systemic evaluation of 
different therapies on cerebral microcirculation after CA is missing in-vivo.  Given the dynamic 
variation of CBF post-CA, the understanding of mechanism for each category of therapy is 
critical to optimize the therapeutic effect on cerebral microcirculation.  Last but not least, the 
translation of therapeutic effect on cerebral microcirculation from pre-clinical models to clinical 
studies is warranted.  Multiple pharmacological agents such as Ca2+ channel blockers failed in 
clinical trials which suggests that the interpretation and application of animal studies should be 
cautious.  Deeper understanding of cerebral microcirculation, in both pre-clinical and clinical 
studies, will bridge the translation of various treatment effect.   
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6.1.2 Pre-clinical Approach to Evaluate Cerebral Microcirculation in-vivo 
In Chapter 3, we established a platform to characterize cerebral microcirculation alterations post-
CA in-vivo using multi-photon microscopy.  To better capture the disturbances, static 
measurements (vessel diameter) and dynamic measurements (RBC and plasma flow) were 
collected in pediatric rats subjected to 9 min asphxial CA.  Two major targets were identified in 
this model: small arterial constriction and RBC stasis in the capillaries- “no-reflow 
phenomenon”.  The finding provides rationales for microvessel dilatory as well as hemodynamic 
agents and paves the way for the evaluation of these therapies. 
In Chapter 4, assessment of a vessel dilator HET0016 was performed in the same model 
and dilatory effect on small arterioles was confirmed in-vivo.  HET0016 had no effect on RBC 
stasis but provided benefit in plasma transit time, indicating dual mechanisms for the two targets 
identified previously.  The results also support the potential of combined treatments to synergize 
their effects and improve cerebral microcirculation post-CA.   
We recognized that we did not assess microcirculatory metabolism in these two chapters. 
This is a major limitation we hope to address in the future studies.  It is possible that flow 
“shunting” is taking place after the resuscitation which could be indicated by shortened MTT. In 
this case the apparently attenuated MTT could confound the interpretation of the result. On the 
other hand, even if the microcirculatory flow is restored, it is still possible that vascular units are 
severely damaged from the injury and no efficient oxygen exchanges are allowed. Therefore it is 
ultimately important to monitor brain tissue oxygenation when we are assessing microcirculatory 
flow alterations.  
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6.1.3 Clinical Approach to Explore Vasoactive 20-HETE as a Biomarker in aSAH 
Patients 
In Chapter 5, we aimed to explore the potential roles of plasma 20-HETE and cerebrovascular 
reactivity as two biomarkers for aSAH patients.  Previously CSF 20-HETE has been associated 
with higher mortality rate and worse outcome in aSAH patients.  It is straightforward to assess 
the correlation between plasma and CSF 20-HETE given the easier access and better 
generalizability of the results.  However, we did not find a correlation between plasma and CSF 
20-HETE.  In subgroup analysis, correlation greatly improved, indicating the involvement of 
local 20-HETE production in the brain and may serve as a new mechanism to predict patient 
outcome.  To reveal the underlying mechanism, pre-clinical models are required to test the 
hypothesis.   
In the interventional, prospective clinical study where we aim to establish the association 
of cerebrovascular reactivity and CSF 20-HETE concentration, we observed different CO2 
reactivity profile in aSAH patients.  We test the clinical feasibility of CO2 reactivity in these 
patients. To depict the profile of cerebrovascular reactivity, more aSAH patients are needed.  To 
validate the profile, modeling simulation would be informative to simulate patient population 
and establish the association.     
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6.2 FUTURE DIRECTION 
6.2.1 Pre-clinical Inferences 
Multiphoton microscopy serves as an ideal platform to unmask the physiological or 
pathophysiological change in real-time and at the cell level.   In our pediatric CA model where 
we observed the “no-reflow phenomenon”, the underlying mechanism remains to be illustrated.  
One possible hypothesis is platelet aggregation and neutrophil infiltration, which can be tested 
under current experimental setting.  By labeling platelet and neutrophils with corresponding 
antibody, their role in “no-reflow phenomenon” could be described.  It is worth noting that 
appropriate control is necessary to distinguish the artificial labeling effect from the actual 
pathophysiological process.   
This tool of multiphoton imaging can also provide evidence for therapeutic mechanism 
because of its high sensitivity and resolution.  The tracking of small molecular drugs in-vivo 
might be limited, because tagging the fluorophore would very likely change the pharmacokinetic 
and pharmacodynamic behavior of the original compound.  However, utilization of this tool to 
reveal the mechanism of big molecules, such as antibodies, long-chain fatty acids and polymers 
is rather promising.  For example, drag-reducing polymer (DRP), a long-chain rheological agent 
with molecular weight over 100kDa, could be evaluated using multiphoton microscopy.  
Previously it has been reported that DRP can improve microcirculatory blood flow and 
oxygenation in a rat model of TBI [313].  The benefit of DRP in our pediatric CA model has also 
been evaluated in the preliminary study.  However, the mechanism of DRP, especially the 
location where the drag-reducing effect takes place, has not been characterized in-vivo.  By 
tagging a fluorophore at the end of each DRP and injecting intravenously, evidence of this 
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polymer could be provided to illuminate its mechanism of reaction.  Another potential use of this 
tool is immunotherapy (eg. Bevacizumab) in CNS tumors, where traditional pharmacokinetic 
and pharmacodynamic models are not good enough.  Multiphoton imaging could detail the 
spatial and temporal information of antibody on the tumor site, which enables better application 
of the therapy.   
Besides the microcirculatory flow, the characterization of metabolism in microcirculation 
is also very important.  Earlier studies suggest a mismatch between flow and metabolism post-
CA [314].  This means that an apparent increase in flow might be a waste and certain brain 
region might still suffer hypoxia.  To address this issue, flow shunting vessels could be 
quantified post-CA and studied with different therapies.  Nemoto, et al. demonstrated the 
feasibility of quantifying shunted microvessel when ICP increased [315].  The autofluorescence 
of NADH/NADPH has also been suggested as a metabolism marker [315].  At wavelength 
around 700-750 nm, NADPH can be excited. By quantifying autofluorescence pre- and post-CA 
can provide useful information about neuronal activity and metabolism post-CA.   
Limitations of multiphoton microscopy do exist.  Besides the expensive cost of the 
instrument and theoretical limitations such as high phototoxicity and certain imaging depth, one 
limitation is the high inter-individual variability.  To prepare an animal for multiphoton imaging 
is delicate and time-consuming.  The imaging locations are limited by the prepared window.  The 
observations could be affected by the specific location and sampling strategy.  Repeated 
observations and subjects are essential to overcome the inter-individual variability with 
appropriate statistical methods.  Another limitation is the relative descriptive and qualitative 
evidence compared with quantitative methodology.  The spatial resolution in current experiment 
setting is 1 µm while the diameter of small capillary is 3~5 µm.  The quantification of these 
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capillaries should be cautiously and consistently done with appropriate blindness.  Therefore, 
multiphoton imaging is more descriptive method to reveal the mechanism in a process, rather 
than a quantitative method to distinguish different effects. 
6.2.2 Clinical Inferences 
Although multiphoton microscopy could not be used in clinical studies at this moment, our 
results from chapter 3 and 4 proposed novel therapeutic targets with underlying mechanism 
which has translational significance.  We utilized a clinically relevant rat model in our 
assessment and the physiology changes are well-documented and close to patients as much as 
possible.  The resuscitation protocol used in this study is also adjusted to follow clinical practice.  
The two targets we identified in animal model could apply to patients and provide supportive 
evidence to microvessel dilators and hemodynamic agents.  More importantly, we observed the 
arteriolar dilatory effect of HET0016 in-vivo post-CA.  This further supports the rationale of 
developing microvessel dilators, especially targeted on 20-HETE pathways for clinical use.   
Besides new compound development, another clinical strategy to assess 20-HETE as a 
biomarker in neurovascular diseases.  Based on sample availability, we applied this strategy in 
aSAH patients.  Despite the lack of correlation between plasma and CSF 20-HETE levels in all 
samples collected, the improved correlation identified in subgroup analysis suggested a burst 20-
HETE local production in certain aSAH patients.  In this situation, sampling plasma 20-HETE 
cannot represent the true level in the brain and mislead the interpretation.  Cautions are also 
warranted for other paraendocrine molecules.  If there is a burst production of 20-HETE and 
contributes to worse outcome, genetic or epigenetic factors could be used to identify these 
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patients.  It also provides information for future development of treatment targeted on 20-HETE 
pathway: quick distribution, great brain penetration and prophylactic dosing strategy.   
We observed a spread range of cerebrovascular reactivity in only 5 aSAH patients in the 
prospective clinical study.  Although no pattern could be identified, we saw temporal and 
asymmetric variations even within the same patient.  This is very informative since previously 
proposed parameters such as Normalized Autoregulatory Response or Vasomotor Reactivity is 
not able to describe patient profile.  Without an appropriate measurement of vascular reactivity, 
no plausible prediction or correlation could be established between reactivity and patient 
outcome.  Therefore, there is an urgent need to establish a new measurement to fully capture 
patient cerebrovascular reactivity profile, taking duration of lack of reactivity, either/both sides 
lack of reactivity, the extent of lack reactivity and super reactivity into account.  This is a 
necessary step to validate cerebrovascular reactivity as a clinical biomarker to tailor treatment or 
predict patient outcome. 
To conclude, the cerebral microcirculation serves as a key player in neurovascular 
diseases such as CA and SAH.  Alterations identified in cerebral microcirculation using 
multiphoton microcopy indicates new therapeutic targets and can be further explored using pre-
clinical and clinical approaches.  Biomarkers in cerebral microcirculation provides new insights 
in identifying vulnerable patient population and personalize treatment.    
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A.1 APPENDIX I 
Comprehensive literature search strategy generated for systemic review.  This strategy generated 
1063 items in PubMed. 
 ((("Heart Arrest"[Mesh] OR Asystole[tw] OR “cardiac arrest”[tw] OR Cardiopulmonary 
arrest*[tw] OR Cardiovascular arrest*[tw] OR “circulatory arrest”[tw] OR “heart arrest”[tw] OR 
“Postcardiac arrest”[tw] OR “Post-cardiac arrest”[tw] OR postresuscitation[tw] OR ROSC[tw] 
OR "four-vessel occlusion"[tw] OR "4-vessel occlusion"[tw] OR “neck tourniquet”[tw])) AND 
((("Brain/blood supply"[Mesh] OR "Brain/metabolism"[Mesh] OR "Cerebrovascular 
Circulation"[Mesh] OR "Cerebral Cortex/blood supply"[Mesh] OR "Cerebral 
Cortex/metabolism"[Mesh] OR "Hypoxia, Brain"[Mesh] OR "Neurons/blood supply"[Mesh] OR 
"brain oxygen"[tw] OR "brain oxygenation"[tw] OR "Cardiocerebral resuscitation" [tw] OR 
"cerebral blood flow" [tw] OR "cerebral microcirculatory perfusion" [tw] OR "cerebral oxygen" 
[tw] OR "cerebral oxygenation" [tw] OR "cerebral oximeter" [tw] OR "Cerebral oximetry"[tw] 
OR "cerebral perfusion" [tw] OR "cerebral protection" [tw] OR "Cerebral resuscitation"[tw] OR 
"Cerebral saturation" [tw] OR "Cerebrovascular circulation"[tw] OR Ischemic 
Encephalopath*[tw] OR "J Cereb Blood Flow Metab"[jour])) OR ("Regional Blood 
Flow"[Mesh] AND ("brain"[MeSH Terms] OR "brain"[All Fields])))) AND 
("Acetylcysteine"[Mesh] OR "Acid-Base Equilibrium"[Mesh] OR "Acidosis/drug 
therapy"[Mesh] OR "Adenosine"[Mesh] OR "Amiloride"[Mesh] OR "Angiotensin II"[Mesh] OR 
"Antioxidants"[Mesh] OR "Antithrombins"[Mesh] OR "Argon"[Mesh] OR "Blood 
Substitutes"[Mesh] OR "Blood Viscosity"[Mesh] OR "Blood Volume"[Mesh] OR 
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"Buffers"[Mesh] OR "Carbonates"[Mesh:NoExp] OR "Deferoxamine"[Mesh] OR 
"Diltiazem"[Mesh] OR "Dopamine"[Mesh] OR "Endothelins"[Mesh] OR "Epinephrine"[Mesh] 
OR "Fibrinolytic Agents" [Pharmacological Action] OR "Fibrinolytic Agents"[Mesh] OR 
"Flunarizine"[Mesh] OR "Hematocrit"[Mesh] OR "Hemodilution"[Mesh] OR "Heparin"[Mesh] 
OR "Hydrogen/therapeutic use"[Mesh] OR "Hydrogen-Ion Concentration"[Mesh] OR 
"Hydroxyeicosatetraenoic Acids/antagonists and inhibitors"[Mesh] OR "Hyperbaric 
Oxygenation"[Mesh] OR "Hypertonic Solutions/administration and dosage"[Mesh] OR 
"Hypertonic Solutions/therapeutic use"[Mesh] OR "Methoxamine"[Mesh] OR "N-acetylcysteine 
lysinate" [Supplementary Concept] OR "Neuroprotective Agents"[Mesh] OR “Neuroprotective 
Agents" [Pharmacological Action] OR "Nitrates"[MeSH Terms] OR "Nitrites"[MeSH Terms] 
OR "Nitric Oxide"[Mesh] OR "Nitroglycerin"[Mesh] OR "Nitroprusside"[Mesh] OR 
"Norepinephrine"[Mesh] OR "Pentoxifylline"[Mesh] OR "Plasma Substitutes"[Mesh] OR 
"Phenylephrine"[Mesh] OR "Phenytoin"[Mesh] OR "Plasminogen Activators"[Mesh] OR 
"Poly(ADP-ribose) Polymerases/deficiency"[Mesh] OR "Poly(ADP-ribose) 
Polymerases/metabolism"[Mesh] OR "Pyruvates"[Mesh] OR "Saline Solution, 
Hypertonic"[Mesh] OR "simendan" [Supplementary Concept] OR "Sodium Bicarbonate"[Mesh] 
OR "Streptokinase"[Mesh] OR "Superoxide Dismutase"[Mesh] OR "Sympathomimetics"[Mesh] 
OR "tempol" [Supplementary Concept] OR "Thiopental"[Mesh] OR "Thrombolytic 
Therapy"[Mesh] OR "tirilazad" [Supplementary Concept] OR "Urokinase-Type Plasminogen 
Activator"[Mesh] OR "Vasodilator Agents"[Mesh] OR "Vasopressins"[Mesh] OR 
"Xenon"[Mesh] OR Adrenaline[tw] OR “alkaline buffer”[tw] OR Anistreplase[tw]  OR 
Antioxida*[tw]  OR Buffer[ti] OR Cardizem[tw] OR Epinephrine[tw] OR Freedox[tw] OR 
HET0016[tw] OR “20-HETE”[tw] OR Levophed[tw] OR Levosimendan[tw] OR “Methyl 
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isobutyl amiloride”[tw] OR “N-Acetylcysteine”[tw] OR Neo Synephrine[tw] OR 
Neuroprotection[tw] OR neuroprotective[tw] OR Nitroglycerin[tw] OR Nitropress[tw] OR 
Nitrostat[tw] OR Noradrenaline[tw] OR “PARP-2 deletion”[tw] OR “Sodium Nitroprusside”[tw] 
OR Streptodornase[tw] OR Streptokinase[tw] OR “Tissue Plasminogen Activator”[tw] OR 
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Norepinephrine α-1, α-2, β1agonist pig microspheres VF increase CBF 
[48, 221, 
323] 
Phenylephrine α-1 agonist pig microspheres VF increase CBF [40, 316] 
Methoxamine α-1 agonist dog microspheres VF increase CBF [42] 
Dexmedetomidine α-2 agonist dog microscopy VF 
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mouse MRI KCl no effect on CBF [92] 








NO donor pig, rat 
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two-photon microscopy 
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pig microspheres VF 











pig laser Doppler flowmetry 
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pig laser Doppler flowmetry VF increase CBF [110] 
7-nitroindazole(7-
NI) 
nNOS inhibitor rat laser Doppler flowmetry 
4-vessel 
occlusion 





eNOS inhibitor pig laser Doppler flowmetry 
4-vessel 
occlusion 












pig microsphere asphyixal increase CBF [128] 
Flunarizine Calcium antagonist dog thermal method VF increase CBF [129, 130] 


















































no effect on CBF [168] 
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y bypass, VF 













pig laser Doppler flowmetry VF 








rat laser-Doppler flowmetry 
bilateral clip 
occlusion of the 
common carotid 
no effect on CBF [183] 
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arteries 
Aspirin Thromboxane A2 rat laser Doppler flowmetry 
four-vessel 
occlusion 







increase CBF [185] 
Pentoxifylline 
antagonist 
of adenosine 2 
receptor and 
increase 











cat fluorescence microscopy VF increase CBF [180] 
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magnetic resonance imaging 
asphyxial attenuate hyperemia [13] 
Methylprednisolo
ne 
anti-inflammatory pig microspheres 
cardiopulmonar
y bypass 





Whole blood  pig microspheres 
cardiopulmonar
y bypass 
decrease CBF [199] 
Diaspirin cross-
linked hemoglobin 
 pig microspheres VF increase CBF [205] 
Liposome-
encapsulated 
 rat laser Doppler flowmetry 
four-vessel 
occlusion 
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y bypass, VF 
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pig, rat, 
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IRB approval letter and the most recent renewal letter 
 
University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
Memorandum 
    
To: Paula Sherwood , RN, PhD 
From: Sue Beers PhD, Vice Chair 
Date: 6/20/2016 
IRB#: PRO16030073 




At its full board meeting on 5/5/2016, the University of Pittsburgh Institutional 
Review Board, Committee D, reviewed the above referenced research study and 
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approved it pending minor modifications.  Your responses to these comments have 
been reviewed and the research submission, in its currently modified form, adequately 
addresses the concerns of the IRB and is therefore approved.   
  
Please note the following information: 
  
The risk level designation is Greater Than Minimal Risk. 
Approval Date:    6/20/2016  
Expiration Date:  5/4/2017 
  
The following documents were approved by the IRB: 
Consent form 
  
For studies being conducted in UPMC facilities, no clinical activities can be 
undertaken by investigators until they have received approval from the UPMC Fiscal 
Review Office. 
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Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) 
and 21 CFR 56.108(b)].  Refer to the IRB Policy and Procedure Manual regarding the 
reporting requirements for unanticipated problems which include, but are not limited 
to, adverse events.   If you have any questions about this process, please contact the 
Adverse Events Coordinator at 412-383-1480. 
The protocol and consent forms, along with a brief progress report must be 
resubmitted at least one month prior to the renewal date noted above as required by 
FWA00006790 (University of Pittsburgh), FWA00006735 (University of Pittsburgh 
Medical Center), FWA00000600 (Children’s Hospital of Pittsburgh), FWA00003567 
(Magee-Womens Health Corporation), FWA00003338 (University of Pittsburgh 
Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically by 





University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 




    
To: Paula Sherwood, RN, PhD 
From: Judith Martin MD, Vice Chair 
Date: 5/17/2018 
IRB#: REN18050039  / PRO16030073 







The Renewal for the above referenced research study was reviewed and 
approved by the Institutional Review Board, Committee C, which met on 5/15/2018. 
 
Please note the following information: 
The risk level designation is Greater Than Minimal. 
  
Approval Date: 5/15/2018 
Expiration Date: 5/14/2019 
  
Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) 
and 21 CFR 56.108(b)].  Refer to the IRB Policy and Procedure Manual regarding the 
reporting requirements for unanticipated problems which include, but are not limited 
to, adverse events.   If you have any questions about this process, please contact the 
Adverse Events Coordinator at 412-383-1480. 
The protocol and consent forms, along with a brief progress report must be 
resubmitted at least one month prior to the renewal date noted above as required by 
FWA00006790 (University of Pittsburgh), FWA00006735 (University of Pittsburgh 
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Medical Center), FWA00000600 (Children’s Hospital of Pittsburgh), FWA00003567 
(Magee-Womens Health Corporation), FWA00003338 (University of Pittsburgh 
Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically by 
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